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Abstract  22 
 23 
Chromatin modifications instruct genome function through spatiotemporal recruitment of 24 
regulatory factors to the genome. However, how these modifications define the proteome 25 
composition at distinct chromatin states remains to be fully characterized. Here, we made 26 
use of natural protein domains as modular building blocks to develop engineered chromatin 27 
readers (eCRs) selective for histone and DNA modifications. By stably expressing eCRs in 28 
mouse embryonic stem cells and measuring their subnuclear localisation, genomic 29 
distribution and histone-PTM-binding preference, we first demonstrate their applicability as 30 
selective chromatin binders in living cells. Finally, we exploit the binding specificity of eCRs to 31 
establish ChromID, a new method for chromatin-dependent proteome identification based on 32 
proximity biotinylation. We use ChromID to reveal the proteome at distinct chromatin 33 
modifications in mouse stem cells, and by using a synthetic dual-modification reader, we 34 
furthermore uncover the protein composition at bivalent promoters marked by H3K4me3 and 35 
H3K27me3. These results highlight the applicability of ChromID as novel method to obtain a 36 
detailed view of the protein interaction network determined by the chemical language on 37 
chromatin. 38 
 39 
 40 
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Introduction 43 
 44 
 Chromatin and numerous chemical modifications on histones and DNA play critical 45 
roles in organismal development and human health 1. These modifications are recognised by 46 
specialised reader domains that exist in numerous regulatory proteins and multiprotein 47 
complexes 2,3. Depending on the presence and composition of modifications at genomic sites, 48 
regulatory factors can associate with chromatin in a spatiotemporal manner 4. However, a 49 
major challenge in the field remains to understand how this chemical language on chromatin 50 
defines the protein interactome of the genome. 51 
 52 
In recent years, proteomics-based assays helped to measure the chromatin interaction 53 
preferences of numerous proteins and to discover their affinity to chromatin marks. Current 54 
methods probe the cellular proteome using synthetic histone peptides, methylated DNA 55 
probes or in-vitro-reconstituted nucleosomes 5-9. In addition, proteomics of specific genomic 56 
segments can be achieved using enrichment via antibodies, DNA sequence-specific probes 57 
or more recently, via engineered dCas9-fusion proteins 10-14. While these studies have greatly 58 
enhanced our current knowledge about interactions between proteins and chromatin marks, 59 
the available methods rely on artificial chromatin, protein-protein crosslinking, or methods that 60 
require access to the underlying DNA, leading to chromatin disruption. Therefore, novel 61 
approaches are required that enable detection of dynamic interactions between proteins and 62 
physiological chromatin in living cells. 63 
  64 
 Here, we developed chromatin-dependent proteome identification (ChromID) to 65 
identify the local proteome composition based on the physiological readout of individual and 66 
combinatorial chromatin marks. Towards this, we used the reader domains from well-67 
established chromatin regulators as modules to build engineered chromatin readers (eCRs). 68 
We first quantified and functionally validated the genome-wide binding and histone-PTM 69 
interaction preferences of individual eCRs towards DNA methylation, H3K9me3, H3K4me3 70 
 4 
and H3K27me3, demonstrating their applicability as selective binders in mouse stem cells. 71 
Finally, we utilised the specificity of eCRs to recruit promiscuous biotin ligases to detect 72 
proteins associated with these individual chromatin modifications in mouse embryonic stem 73 
cells, revealing similarities and differences in the proteome composition between these marks. 74 
By coupling ChromID to a synthetic dual-modification reader, we furthermore detect proteins 75 
associated with genomic regions marked by the bivalent modification H3K4me3 and 76 
H3K27me3.   77 
 5 
Results 78 
 79 
Generation and characterisation of engineered chromatin readers in mouse embryonic stem 80 
cells 81 
 82 
 We first assembled well-characterised chromatin reader domains into synthetic 83 
reporter proteins to test their affinity and specificity for individual chromatin modifications in 84 
living cells. Towards this, we used the chromo domains specific for H3K27me3 from CBX7 85 
and Drosophila Polycomb (dPC) 15,16, the H3K9me3-specific chromodomain from CBX1 17,18, 86 
the Phd domain specific for H3K4me3 from TAF3 19, and the MBD domains from the DNA 87 
methylation readers MBD1 and MeCP2 20,21 (Fig. 1a). cDNA sequences were assembled 88 
either as single- or dual-domain constructs into a protein expression cassette containing a 89 
biotin acceptor site for biochemical purification, a nuclear localisation signal (NLS), and eGFP 90 
for live imaging and detection (Fig. 1a and Supplementary Fig. 1a).  All constructs were 91 
integrated to a defined site in the mouse genome via Recombinase-Mediated Cassette 92 
Exchange RMCE 22, enabling fast generation of stable mESC lines expressing the proteins  93 
from the same genomic location and under the control of the same promoter (Fig. 1b). 94 
Measurements of eGFP fluorescence and protein levels indicated that all generated cell lines 95 
display stable and homogenous expression of the introduced engineered Chromatin Readers 96 
(eCR) at intermediate protein levels (Supplementary Fig. 1b-d). We next performed in vitro 97 
differentiation of mESC to glutamatergic neurons to test if the presence of eCRs interferes 98 
with biological processes relevant for cellular identity and function. All cell lines successfully 99 
differentiated to mature neurons, and we could not observe any differentiation defects in 100 
presence or absence of the eCRs, suggesting that their stable expression does not interfere 101 
with cellular processes (Supplementary Fig. 1e-g). 102 
 103 
Live imaging of stable cell lines with single chromodomain eCRs targeting histone 104 
methylation showed a diffuse nuclear localisation with accumulation in nucleoli, similar to the 105 
 6 
eGFP control lacking reader domains. In contrast, eCRs containing two chromodomains 106 
showed a defined pattern with signals for the CBX1-2xChromo eCR at DAPI-dense 107 
chromocenters and the CBX7- and dPC2-2xChromo eCRs forming discrete subnuclear 108 
aggregates at the nuclear periphery and around nucleoli (Fig. 1c and Supplementary Fig. 2a). 109 
These localisation patterns are identical to what has been reported for the subnuclear 110 
distribution of H3K9me3 and H3K27me3, respectively 23,24 (Supplementary Fig. 2b). In 111 
contrast to the chromodomains, the single and dual TAF3 Phd-domain eCR showed a 112 
homogenous signal throughout the entire nucleus (Supplementary Fig. 2a) as previously 113 
reported for H3K4me3 distribution using antibodies 24. eCRs containing single MBD domains 114 
from MBD1 or MeCP2 co-localised with DNA-methylated, DAPI-dense chromocenters, similar 115 
to their corresponding full-length proteins (Supplementary Fig. 2a) 22. Furthermore, live-cell 116 
imaging of the eGFP-tagged eCRs enabled us to explore their localisation during cell cycle 117 
progression and along the condensed M-phase chromosomes (Supplementary Fig. 2c-e and 118 
Supplementary Videos).  119 
 120 
The results obtained from single and double domain eCRs specific for histone 121 
modifications indicate that one domain is not sufficient to promote localisation and that 122 
multivalent interactions are required. To further validate this, we made use of reconstituted 123 
nucleosomes carrying H3K4me3 or H3K27me3 marks on both histone tails. Pulldown 124 
experiments using recombinant single- or double- domain eCRs indicate robust interactions 125 
only for dual domains, but not for single-domain eCRs, supporting the necessity of multivalent 126 
interactions for stable binding of eCRs to histone-PTMs in vivo (Supplementary Fig. 2f).  127 
 128 
 129 
Functional analysis validates the interaction preference of eCRs with specific chromatin 130 
modifications. 131 
 132 
 7 
 Next, we explored the genome-wide binding patterns of all eCRs by biotin-ChIP-seq 133 
22. By visual inspection of the binding tracks we observed eCR-specific signals corresponding 134 
to the distribution of target histone modifications and DNA methylation, indicating correct 135 
localisation to these marks (Fig. 1d-f and Supplementary Fig. 3a-b). Their selective binding 136 
preference to chromatin modifications was also confirmed by genome-wide enrichments and 137 
direct comparison to histone modifications, DNA methylation and endogenous reader proteins 138 
(Fig. 1g, Supplementary Fig. 3c-d and 4a-d). The signals obtained from individual eCR 139 
datasets indicated their clear distinction in binding to genomic elements modified by the 140 
corresponding target modifications (Supplementary Fig. 5a-d), where eCRs specific for 141 
H3K4me3 preferentially associated with gene promoters, H3K9me3 readers with repetitive 142 
elements, and DNA methylation readers with methyl-CpG-dense exons (Supplementary Fig. 143 
5e). Notably, and in accordance with live-cell imaging, only experiments using eCRs with two 144 
histone-PTM reader domains resulted in detectable binding signals (Supplemental Fig. 3a-b 145 
and 5f), highlighting again the necessity for multivalent interactions for stable target 146 
engagement. 147 
 148 
 To investigate the specificity of eCRs we introduced mutations to the reader domains 149 
known to disrupt binding: CBX1-W42A 25, CBX7-W35A 26, MBD1-R22A 27 and furthermore, 150 
various Rett syndrome mutations in the MeCP2 MBD (R106W, R133C, T158M 28) 151 
(Supplementary Fig. 6a). In all tested instances, we observed that mutations led to a partial 152 
or complete disruption of subnuclear localisation (Supplementary Fig. 6b), as well as loss of 153 
genome-wide binding to chromatin modifications (Fig. 2a-b, d and Supplementary Fig. 6c). 154 
The same disruption of localisation was observed for wild type readers in absence of the 155 
respective chromatin marks, highlighting that binding is fully dependent on the target 156 
modification. This dependency was shown by loss of binding of MeCP2-1xMBD in cell lines 157 
lacking DNA methylation (Dnmt-TKO), and CBX7-2xChromo in cell lines lacking H3K27me3 158 
(Eed-KO) (Fig. 2c and Supplementary Fig. 6d-f). 159 
 160 
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 Next, we employed mass spectrometry as an orthogonal approach to identify the 161 
histone PTMs that are preferentially bound by the eCRs in living cells. Towards this, we 162 
detected and quantified the modifications on histones enriched in ChIP experiments using a 163 
synthetic reference peptide library including 87 individual and combined marks on histone tails 164 
from H2A, H3 and H4 29 (Supplemental Fig. 7a and b). Overall, the enriched histone PTMs 165 
reflect the genome-wide correlations described above, further corroborating the specific 166 
affinity of the reader domains for their substrates in living cells (Fig. 2e). In case of the TAF3-167 
2xPhd eCR, we detect histone H3 tails that carry di- and tri- but not mono-methylation marks 168 
at the lysine 4 residue and furthermore acetylated H3 and H4 (K9, K14 on histone H3 and K5, 169 
K8, K12, K16 on histone H4) (Fig. 2e-f and Supplementary Fig. 7c). Histone H3 tails containing 170 
methylated K9, K27 or K36 residues were generally depleted in the TAF3-2xPhd eCR 171 
pulldowns (Fig. 2e). In contrast, CBX1-2xChromo eCR-enriched histone tails predominantly 172 
carry the H3K9 tri-methyl mark as well as H4K20me3 (Figure 2e-f), a modification co-existing 173 
with H3K9me3 at repetitive heterochromatin 30 (Supplementary Fig. 7d-e). In addition, we also 174 
detect that H3S10-phosphorylation prevents binding of the CBX1-eCR to H3K9me3, as 175 
previously reported for CBX1 in vitro 31 (Fig. 2e,g).  176 
 177 
Taken together, these experiments validate the target specificity of the introduced 178 
eCRs to chromatin marks. Furthermore, the obtained results highlight the suitability of eCRs 179 
as multi-purpose cellular probes to detect the distribution of chromatin modifications in living 180 
cells by live imaging, genomics and proteomics.  181 
 182 
 183 
ChromID reveals the proteome composition at H3K9- and DNA-methylated sites via eCR-184 
mediated proximity biotin labelling 185 
 186 
 Having fully characterised the in vivo binding specificity of eCRs, we wanted to exploit 187 
their genomic localisation to detect the proteome composition at distinct chromatin 188 
 9 
modifications via proximity biotin ligation (Fig. 3a). To this end, we tested three different 189 
promiscuous biotin ligases for their labelling efficiency during 24 hours in murine ES cells: 190 
BirA* R118G-mutant 32, BioID2 33 and BASU 34 (Supplementary Fig. 8a-b). BioID2 and BASU 191 
showed the highest labelling efficiency under these conditions, therefore we used these 192 
ligases in combinations with the specific H3K9me3-reader to establish the optimal conditions 193 
using quantitative label-free LC-MS/MS. The protein-interactome of this mark has been well-194 
described in mammalian cells 5,6, and served as a proof of concept to define optimal settings 195 
for ChromID (Supplementary Fig. 8c-e and Methods). Finally, based on the signal to noise 196 
ratio we chose BASU with 12 hours biotin-treatment followed by highly stringent washing with 197 
SDS as the most-optimal condition.  198 
 199 
 Using these conditions, we identified 58 high-confidence H3K9me3-associated 200 
proteins enriched for Gene Ontology terms linked to pericentric or telomeric heterochromatin, 201 
confirming proteins found in other proteomic approaches and forward screens 5,6,35 36(Fig. 3b-202 
c, Supplementary Fig. 8e and Table 1). Found factors include the H3K9 methyltransferases 203 
SETDB1, EHMT1 and EHMT2 37,38, the HUSH complex component MPP8 39, the chromatin 204 
remodeller ATRX 40, MeCP2 and UHRF1 41, 42. Besides these factors, our method enabled us 205 
to identify zinc finger proteins, which have been linked to heterochromatin (POGZ, WIZ 43,44), 206 
and multiple instances that have not been characterised in the context of heterochromatin 207 
(CASZ1, ZNF24, ZNF292, ZNF512B, ZNF518B, ZNF280B and ZNF280D). To test if the 208 
newly-identified proteins localize to H3K9me3-marked chromatin, we further validated the 209 
localization of the endogenous ZNF280D protein. For this, we endogenously tagged ZNF280D 210 
in mouse ES cells and performed biotin ChIP-seq (Supplementary Fig. 9a-b). Genome-wide 211 
binding of ZNF280D shows a strong localisation preference to H3K9me3 sites, confirming that 212 
ChromID indeed reveals proteins associated with specific chromatin marks (Supplementary 213 
Fig. 9c-d).  214 
 215 
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 We next used ChromID in conjunction with the 5-methyl-CpG-specific eCR (MBD1-216 
1xMBD) resulting in the identification of proteins associated with DNA methylation such as 217 
DNMT1 and UHRF1 45 and proteins enriched for Gene Ontology terms related to 218 
heterochromatin or recognition of DNA replication (Fig. 3d-e, Supplementary Fig. 10a and 219 
Table 2). Besides known factors, we also observed several novel factors that have not been 220 
associated with DNA methylation in ES cells, such as TIF1A (also known as TRIM24), CASZ1, 221 
ZNF512B or TEAD1 (Fig. 3d). The latter was recently found to bind to methylated DNA in HT-222 
SELEX experiments 46. To test the specificity of these interactions for DNA methylation 223 
readout, we repeated these experiments using the mutant 5mC-reader (MBD1-1xMBD-R22A) 224 
fused to BASU. We did not detect any significantly enriched proteins with the mutant 5mC-225 
reader, suggesting that the identified proteins associate with DNA methylation (Fig. 3d and 226 
Supplementary Fig. 10a-c).  227 
 228 
Engineered readout of combinatorial histone PTMs enables identification of proteins 229 
associated with monovalent and bivalent chromatin. 230 
 231 
 Nucleosomes bivalently modified by H3K4me3 and H3K27me3 are found at 232 
developmental gene promoters and are thought to poise their expression for timely activation 233 
47-49. Addressing the genomic distribution and/or protein composition of bivalently modified 234 
sites and other combinatorial modifications has been a major challenge due to lack of tools 235 
that enable simultaneous detection of both marks. To overcome this limitation, we first 236 
characterised synthetic readers engineered for simultaneous detection of H3K4me3 and 237 
H3K27me3 on the same nucleosome. eCRs containing the CBX7-Chromodomain or the dPC-238 
Chromodomain fused to the TAF3-Phd domain were stably expressed in ES cells as described 239 
above (Supplementary Fig. 11a-b). Genome-wide binding analysis indicates preferential 240 
binding of these bivalent eCRs to genomic sites marked by both H3K4me3 and H3K27me3 241 
modifications, while regions containing either H3K4me3 or H3K27me3 were not enriched to 242 
the same levels (Fig. 4a-c and Supplementary Fig. 11c-e). Monovalent eCRs with affinity to 243 
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H3K4me3 or H3K27me3 only, showed reduced enrichments to bivalent regions, while being 244 
predominantly recruited to sites modified by H3K4me3 or H3K27me3, respectively (Fig. 4a-b 245 
and Supplementary Fig. 11c,f). To test the requirement of both domains for the observed 246 
binding, we introduced mutations in either the TAF3-Phd (DW890/891AA 19) or the CBX7-247 
Chromo domains (W35A 26) of the bivalent reader. We observe loss of binding at bivalent sites 248 
for both mutant variants (Supplemental Fig. 12a-c). To further evaluate the requirement of 249 
both histone modifications for recruitment of the bivalent readers, we have introduced the 250 
TAF3-CBX7-bivalent eCR to Eed-KO ES cells lacking H3K27me3. In absence of H3K27me3, 251 
the bivalent reader fails to bind to the genome (Supplemental Fig. 12d-e), further supporting 252 
the finding that its binding is dependent on multivalent readout of both modifications by the 253 
two reader domains. Importantly, mutations in the reader domains or absence of H3K27me3 254 
lead to complete loss of binding to the genome with no additional binding observed at 255 
H3K4me3- or H3K27me3-marked sites, further indicating that the bivalent readers are specific 256 
for bivalently modified nucleosomes. Taken together, the modular architecture of eCRs opens 257 
new possibilities to study and manipulate combinatorial modifications in living cells. 258 
 259 
 The differences in genomic binding observed for the monovalent and bivalent eCRs 260 
encouraged us to perform ChromID with eCRs specific to H3K4me3, H3K27me3 and bivalent 261 
nucleosomes. In total, 136 unique proteins that directly or indirectly interact with the chromatin 262 
marks were found significantly enriched across these three datasets (Supplementary Fig. 13a-263 
b and Table 1). A total of 125 proteins were detected at H3K4me3 (TAF3-eCR), enriching for 264 
GO terms related to transcriptional regulation and H3K4me3 (Fig. 5a), including several 265 
transcription factors, bromodomain proteins, histone modifier and chromatin remodelling 266 
complexes, as well as members of the Transcription Factor IID (TFIID), Integrator-, Mediator- 267 
and Super Elongation-complexes (Supplementary Fig. 13a-b and Table 1). Notably, we also 268 
detect proteins involved in co-transcriptional processes such as the RNA-specific adenosine 269 
deaminase ADAR1 and the histone mRNA 3' end processing factor CASP8AP2/FLASH 50 to 270 
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be associated with H3K4me3, which we confirmed by comparing genomic co-localisation of 271 
FLASH and H3K4me3 at transcribed histone genes (Fig. 5b).  272 
 273 
 The H3K27me3-reader enabled us to identify 20 high-confidence hits, enriching for 274 
GO terms associated with Polycomb repressive complexes and histone methyltransferases 275 
(Fig. 5a, Supplementary Fig. 13a-b and Table 1). Among those hits we observed well-studied 276 
subunits of PRC1 and PRC2 (RING2, EZH2, MTF2 and JARD2). Notably, we also identified 277 
factors involved in H3K9 methylation like SETDB1 or the zinc finger proteins WIZ and 278 
ZNF518B, suggesting a potential crosstalk between proteins bound at H3K9me3 and 279 
H3K27me3 sites. Importantly, this is not due to unspecific localisation of the H3K27me3 280 
readers to H3K9me3 or vice versa, since we do not observe this cross-reactivity from our 281 
ChIP-seq data (Supplementary Fig. 13c). Furthermore, by performing ChromID with the 282 
H3K27me3-specific readers in ES cells lacking H3K27me3 (Eed-KO), we would expect that 283 
such unspecific interactions would persist. However, we fail to detect any enriched proteins, 284 
indicating that the reported interactions indeed originate from H3K27me3 sites 285 
(Supplementary Fig. 13d).  286 
 287 
 Finally, the combinatorial recognition of bivalent H3K4me3 and H3K27me3 loci by the 288 
CBX7-TAF3-eCR enabled us to discover 33 high-confidence factors associated with bivalent 289 
chromatin, enriched in GO terms related to transcriptional activation and repression (Fig. 5a, 290 
Supplementary Fig. 13a-b and Table 1). These included catalytic subunits or components of 291 
the MLL1/MLL2, the NSL histone acetyltransferase and the TFIID basal transcription factor 292 
complex, although TFIID components were detected at lower levels compared to results 293 
obtained with the monovalent H3K4me3 reader. Other factors include enhancer of Polycomb 294 
homolog (EPC1 and EPC2) and components of the NuA4 histone acetyltransferase (HAT) 295 
complex 51,52. Corroborating our findings, a recent study mapped the catalytic subunit of the 296 
NuA4 complex (TIP60) to bivalent regions in mouse ES cells 53. Interestingly, we also identified 297 
the histone lysine 9 and 36 demethylase KDM4C/JMJD2C 54,55 that colocalises with EZH2 in 298 
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mouse ES cells 56, and PHF8, a demethylase involved in removal of H3K9me2, H3K27me2 299 
and H4K20me1-residues 57,58. Among the core components of the PRC1 and PRC2 300 
complexes, we also detected BCOR, MGAP and LMBL2 which are part of the alternative 301 
PRC1.1 and PRC1.6 complexes 59. Notably, we also observe the methylcytosine dioxygenase 302 
TET1 and the transcriptional repressor SIN3A being associated to bivalent sites, in line with 303 
previous genomic studies showing TET1 and SIN3A at bivalent promoters in ES cells 60. 304 
Finally, we introduced the bivalent reader in ES cells lacking H3K27me3 and performed 305 
ChromID to control for false-positive proteins stemming from unspecific interactions of the 306 
readers with marks outside of nucleosomes modified by H3K27me3 and H3K4me3. In this 307 
case we could not identify any significantly enriched proteins, indicating that the reported 308 
proteins are indeed localised to bivalently-modified regions in the genome (Supplementary 309 
Fig. 13e).  310 
 311 
To exclude that the BASU biotin ligase could influence genomic localisation of the 312 
readers and therefore falsely report proteins from sites not decorated by the targeted 313 
modifications, we performed biotin-ChIP-seq of the eCR-BASU constructs and compared their 314 
binding to the previously-obtained datasets of eGFP-fusion constructs (Supplementary Fig. 315 
14a-c). Based on our genome-wide analysis, binding was highly correlated between the same 316 
readers fused to either eGFP or BASU, indicating that the reader domains are not influenced 317 
by the addition of the biotin ligase. In summary, these results highlight the applicability of 318 
modular eCRs as a platform for biotin ligase recruitment, enabling successful identification of 319 
the associated proteins of chromatin subtypes. 320 
 321 
 322 
Integrative analysis of ChromID datasets reveals the chromatin preference of regulatory 323 
proteins 324 
 325 
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Based on the combined datasets from all ChromID experiments we investigated the 326 
distribution of proteins between the different chromatin states, revealing proteins shared 327 
between multiple chromatin states, and proteins specific to single chromatin modifications. 328 
The latter was most prominent for H3K4me3-associated proteins (Fig. 5c, Supplementary Fig. 329 
15a). Notably, several proteins identified at H3K27me3 or bivalent regions were also 330 
associated with H3K4me3, which is expected given the overlap of these modifications in ES 331 
cells 47,48. In addition, we found multiple proteins shared between H3K9me3 and H3K27me3, 332 
while little overlap was found between the H3K9me3 set and proteins detected by H3K4me3 333 
or bivalent regions (Fig. 5c and Supplementary Fig. 15a). Given the well-established crosstalk 334 
between DNA methylation and H3K9me3, we identified a substantial overlap between these 335 
sets (Supplementary Fig. 15b). The functional relationship of the detected factors was further 336 
visualised from high-confidence interaction scores obtained from the STRING database 61, 337 
revealing a strong interconnectivity between proteins and complexes associated with 338 
H3K4me3 and bivalent regions or with heterochromatin marked by H3K9me3 or H3K27me3 339 
(Fig. 5d). 340 
 341 
To obtain a quantitative view on the distribution of regulatory proteins along the 342 
interrogated chromatin marks, we clustered factors from different regulatory groups based on 343 
their enrichment across all datasets (Fig. 5e). For transcription factors, we observed several 344 
associations with H3K4me3 regions (e.g. SP2, MAX, FOXK2, ZFX). In addition, several TFs, 345 
mainly uncharacterised ZNF proteins, are associated with DNA methylation (ZNF280B, 346 
ZNF292, ZNF462, CASZ1, TCF20) and we also recover TFs previously identified to interact 347 
with methylated DNA in pull-down or HT-SELEX assays (KLF4, RREB1, ZNF191/24) 9,46 (Fig. 348 
5e). Similar to TFs, chromatin remodellers separate into a group predominantly associated 349 
with H3K4me3 (e.g. BRD2, BRD4, INO80, CECR2), and a group preferentially associated with 350 
closed chromatin (e.g. ATRX, BAZ2A, SMARCA1). Chromatin writers such as H3K4-specific 351 
methyltransferases (KMT2A, KMT2B) and histone acetyltransferases (EP300) were 352 
preferentially located at H3K4me3, while writers of repressive marks associated with DNA 353 
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methylation, H3K9me3 and/or H3K27me3 (DNMT1, EHMT1/2, NSD1, EZH2). Furthermore, 354 
and in line with genome-wide binding data, erasers such as KDM2A, KDM2B, TET1 or KDM5A 355 
were predominantly found at H3K4me3 sites, and we find several DNA repair factors 356 
associated with repressive chromatin marks (Fig. 5e). Taken together, these datasets 357 
obtained by ChromID provide a valuable resource of chromatin-mediated protein interactions 358 
in the ES cell genome.  359 
 16 
Discussion 360 
 361 
 Here we present ChromID, a quantitative approach that enables identification of 362 
proteins associated with individual and combinatorial chromatin modifications in living cells. 363 
ChromID takes advantage of the affinity of engineered chromatin readers, which we obtained 364 
from natural reader domains of well-characterised chromatin regulators (CBX1, CBX7, dPC, 365 
TAF3, MBD1 and MeCP2). First, we characterised and functionally validated the binding 366 
selectivity of all eCRs using a series of quantitative and functional methods in mouse ES cells. 367 
The obtained results highlight the applicability of eCRs as an alternative to antibodies for 368 
studying subnuclear localisation, genome-wide distribution and histone-PTM combinations in 369 
living cells. Interestingly, single domain eCRs were often insufficient to achieve binding to 370 
histone modifications under physiological conditions. This is in line with several well-known 371 
examples where binding of full-length proteins or complexes to chromatin rely on multivalent 372 
interactions 62-64, including recent studies that introduced synthetic chromatin readers for 373 
immunofluorescence or activation of reporter genes 65-67. We made use of the required 374 
multivalent interactions to generate synthetic readers that recognise two modifications on the 375 
same nucleosome. This allowed us to directly target genomic sites that are bivalently marked 376 
by H3K4me3 and H3K27me3, providing novel tools to study and manipulate chromatin 377 
modifications in a context-dependent manner.  378 
 379 
Finally, to identify the chromatin-associated proteome, we developed ChromID where 380 
we use the eCRs to tether promiscuous biotin ligases to chromatin, resulting in biotinylation 381 
of proteins in a ~ 35 nm radius around the modification of interest. This allowed us to detect 382 
proteins that directly and indirectly associate with chromatin modifications including DNA 383 
methylation, H3K4me3, H3K27me3 and H3K9me3, resulting in a total of 518 identified 384 
proteins. Among these we identified 180 high-confidence proteins enriched across all 385 
datasets, enabling us to assign factors based on their preference towards single or multiple 386 
chromatin marks. By employing the bivalent reader, we further achieved specific identification 387 
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of proteins bound at sites marked by H3K4me3 and H3K27me3, revealing the presence of 388 
activating and repressing proteins from Trithorax and Polycomb complexes and additional 389 
factors that could play a role in chromatin regulation at bivalent sites.  390 
 391 
 Overall, the results from the individual and combinatorial measurements highlight 392 
ChromID as a novel approach to uncover how protein recruitment is influenced by chromatin 393 
modifications in living cells. Importantly, the usage of natural reader domains in ChromID 394 
mimics physiological engagement of proteins with chromatin. This has several benefits, since 395 
the eCR-mediated interactions do not require crosslinking or single-stranded DNA. Another 396 
benefit of ChromID is the usage of proximity biotin ligation to label and subsequently identify 397 
the proteins associated with different chromatin flavours in a unified manner. This enables 398 
comparative studies between different chromatin modifications, circumventing the necessity 399 
of antibodies, which have always been limiting in such assays due to their variation in affinity 400 
and avidity, lack of availability and cost. Furthermore, once biotinylated, the proteins are 401 
enriched using highly-stringent washing and elution conditions, ensuring effective removal of 402 
background signals and reproducible detection and multi-sample comparison.  403 
 404 
We expect ChromID to be used to chart the genome-wide proteome at multiple 405 
chromatin modifications and in numerous cell types in order to understand how the chemical 406 
language on chromatin directs protein recruitment in a spatiotemporal manner. The 407 
applicability of ChromID in living cells, as well as eCRs as synthetic readers, further opens the 408 
possibility to perform similar experiments in a tissue-specific manner in living animals, 409 
providing exciting future avenues to chart the epi-proteome during dynamic cellular processes 410 
and development.   411 
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Methods 458 
 459 
Molecular cloning: 460 
DNA encoding for wild type and mutant domains were amplified from cDNA or synthesized 461 
(IDT technologies) based on available domain annotations (Uniprot). These sequences are 462 
introduced in-frame into the EcoRV site of the RMCE-targeting vector parbit-v6 by Gibson 463 
assembly. The final construct expresses the N-terminal biotin-tagged domain of interest fused 464 
in-frame to a cassette containing an NLS signal followed by eGFP, an internal ribosome entry 465 
site (IRES) and the puromycin-N-acetyltransferase gene (pac), which confers resistance 466 
against puromycin treatment. All coding sequences are under control of a constitutive CAG 467 
promoter. BioID2-HA and the 13X-Linker were PCR amplified from MCS-13X-Linker-BioID2-468 
HA plasmid (Addgene, plasmid #80899), HA-BASU was PCR amplified from BASU-RaPID 469 
plasmid (kindly provided by Paul Khavari; equivalent to Addgene plasmid #107250). PCR-470 
amplified products were cloned into RMCE-targeting vector L1-CAG-NLS-IRES-pac-1L 471 
(parbit-v9) using Gibson assembly. For bacterial expression of eCR-eGFP-6xHis fusion 472 
proteins, sequences spanning the domains of interest along with the NLS and eGFP were 473 
PCR amplified from parbit-v6 and subcloned into a modified pET-28 vector encoding an in-474 
frame C-terminal 6xHis affinity tag.  475 
 476 
Cell culture and cell line generation: 477 
Mouse embryonic stem cells (129×C57BL/6) were cultured on 0.2% gelatin-coated dishes in 478 
ES medium containing DMEM (Invitrogen; ), supplemented with 15% fetal bovine serum (FBS; 479 
Invitrogen), 1x non-essential amino acids (Invitrogen), 2mM L-glutamine (Invitrogen), 0.01% 480 
2-mercaptoethanol (Sigma Aldrich), and homemade leukaemia inhibitory factor (LIF) at 37 °C 481 
in 7% CO2. Cell lines were obtained by recombinase-mediated cassette exchange (RMCE). 482 
Briefly, engineered chromatin-reader containing RMCE constructs were co-transfected with a 483 
CRE recombinase expression plasmid (1: 0.6 μg DNA ratio) to RMCE-competent and biotin 484 
ligase (BirA)-positive mouse ES cell lines 22. Two rounds of selection were applied to yield a 485 
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homogenous population of eCR expressing cells: i) cells that did not exchange the RMCE-486 
cassettes were first removed by negative selection (3mM ganciclovir for 4 days), ii) cells 487 
expressing the eCR of interest were retained by positive selection (2mM puromycin for 2 488 
days). Homogenous and stable protein expression was then monitored by measuring eGFP 489 
expression using flow cytometry, immunofluorescence (IF) and immunoblotting. Transfections 490 
were carried out using Lipofectamine 3000 reagent (Thermo Fisher Scientific, L3000015) at a 491 
2:1 μg DNA ratio in OptiMEM medium (Thermo Fisher Scientific, 31985070). The Eed-KO cell 492 
line was generated by transfecting px330 with a guide (GGTGAAAAAATAATGTCCTG) 493 
targeting exon 8 together with a recombination-repoter 68. 36 hours after transfection, cells 494 
were treated with 2 ug/ml puromycin for 36 h. Single ES cell colonies were harvested and 495 
gDNA was screened by PCR (forward primer: GAGGCACTAGGTGAAAACTGGA, reverse 496 
primer: CACAGAGCCTGTCACCTGTT). Positive KO clones were validated by Sanger 497 
sequencing (Microsynth) and H3K27me3 Western blotting. The endogenously tagged 498 
Zfp280D cell line was generated with a guide (AGTAGACCTGGCAGATGGAG) targeting exon 499 
22, using the same approach outlined above. 72 hours after transfection, single GFP-positive 500 
cells were sorted into 96-wells by flow cytometry. Single ES cell colonies were harvested and 501 
gDNA was screened by PCR (forward primer: AGCACAAATCCCACTGAAGCTG, reverse 502 
primer: TCGTGCCATTCGATTTTCTGAGC). Positive clones were validated by Sanger 503 
sequencing. Neuronal differentiation of ES cells was performed as previously described 69. 504 
 505 
Flow cytometry:  506 
Cells were harvested by trypsinisation and resuspended in DPBS for analysis. If necessary, 507 
cells were incubated with LIVE/DEADTM Fixable Near-IR Dead Cell Stain (Invitrogen, 508 
L34975) to discriminate cell viability. Samples were analysed for eGFP expression and 509 
LIVE/DEADTM stain by flow cytometry on a FACSCanto (BD Biosciences). Cells were gated 510 
for viable and individual cells, channel voltages for eGFP (Alexa Fluor 488-A) and live/dead 511 
(APC-Cy7A) signals were set regarding verified negative and positive eGFP-expressing 512 
control cells. Raw files were analysed and visualised using FlowJo software (Tree Star; 513 
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version 10.0.7). For CD24 measurements in neuronal progenitors, single cell suspensions 514 
were obtained from neuronal progenitors after 8 days of differentiation through trypsinization 515 
and filtered through 40-um cell strainers (BD Biosciences), as previously described 69. For cell 516 
surface staining cells were incubated for 30 min at 4°C with saturating concentration of anti-517 
CD24a monoclonal antibody in the presence of anti-CD16/CD32 (eBioscience). For live dead 518 
cell exclusion LIVE/DEAD Fixable Near-IR Dead Cell Stain (Invitrogen) was used. Samples 519 
were acquired using FACSFortessa (BD Biosciences) and data were analysed using FlowJo 520 
software (Tree Star). 521 
 522 
Western blotting:  523 
For western blotting, 20 μg of protein were resolved in NuPAGE-Novex Bis-Tris 4–12% 524 
gradient gels (Invitrogen) and transferred on polyvinylidene fluoride (PVDF) membranes in a 525 
tank containing transfer buffer (50mM Tris, 0.4M glycine, 0.05% SDS, and 20% MeOH). The 526 
membrane was washed once with TBST (10mM Tris pH 8.0, 150mM NaCl, and 0.1% Tween-527 
20), blocked with 5% (w/v) BSA in TBST, and stained with the corresponding primary antibody 528 
anti-HP1b/CBX1 (1:1,000, CST; #8676) or Lamin B1 (1:1000, Santa Cruz, sc-374015) at 4°C 529 
overnight. After washing three times with TBST for 10 minutes, the signal was detected with 530 
corresponding species-specific horseradish peroxidase (HRP)-conjugated secondary 531 
antibodies. Three additional TBST washes were applied prior protein detection using the 532 
Amersham ECL Western blotting detection reagent (GE Healthcare Life Sciences; RPN2109) 533 
with subsequent signal development on Amersham Hyperfilm ECL (GE Healthcare Life 534 
Sciences; 28906836). For validation of Eed-KO cell lines, cells were lysed with NETN buffer 535 
(20 mM Tris (pH 8), 0.5 % (v/v) NP-40, 100 mM NaCl, 1 mM EDTA (pH 8)) supplemented with 536 
1 x protease inhibitor cocktail (Roche; COEDTAF-RO) and 1 mM DTT (Sigma Aldrich, DTT-537 
RO). Nuclei were pelleted at 6,500 x g for 10 min at 4 °C, washed once with NETN. Histones 538 
were acid-extracted overnight at 4 °C in 0.2 N HCl at a density of 4 x 107 nuclei per ml. Histone 539 
extracts were then centrifuged at 6,500 x g for 10 min at 4 °C to pellet debris and 5 ug were 540 
loaded onto a NuPAGE-Novex 16% Tris-Glycine Gel (Invitrogen). Western Blot and protein 541 
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detection were performed as above with a transfer buffer containing no SDS, but 20 % MeOH, 542 
and membrane was stained with primary antibody anti-H3K27me3 (Diagenode, C15410195), 543 
anti-Histone H1 (Millipore, 05-457) and anti-Histone H3 (Abcam, ab1791). 544 
 545 
Live-cell imaging and image processing:  546 
2x 10^4 eCR-eGFP fusion expressing cells were seeded on 0.2% gelatin-coated 35-mm glass 547 
bottom chambers (Ibidi; 80826) one day before imaging. Next day, cells were stained with 548 
Hoechst 33342 (Invitrogen; 62249) for 10 minutes, washed twice with DPBS, and covered 549 
with ES cell imaging medium containing DMEM (Invitrogen; 31053028), supplemented with 550 
15% foetal bovine serum (FBS; Invitrogen), 1x non-essential amino acids (Invitrogen), 2mM 551 
L-glutamine (Invitrogen), 0.01% 2-mercaptoethanol (Sigma Aldrich), and homemade 552 
leukaemia inhibitory factor (LIF). Randomly selected cells were imaged with sequential 553 
acquisition settings on a Leica SP5 inverted confocal laser scanning microscope equipped 554 
with a climate chamber, an Argon laser for 453, 476, 488, 496, and 514 nm, and a diode laser 555 
for 561 nm. The filters for fluorescence imaging were GFP (ex BP 470/40, em BP 525/50) and 556 
N3 (ex BP 546/12, 600/400). Confocal images were acquired with an HCX PL APO Leica 63× 557 
oil immersion objective with HyD detectors. Z stacks were acquired per site using a 0.3 µm 558 
step size.  559 
Time-lapse fluorescence microscopy was performed with a confocal spinning disk imaging 560 
system (Olympus IXplore SpinSR10, Olympus Corporation) equipped with a CSU-W1 unit 561 
(YOKOGAWA) and a 60× UPLSAPO UPlan S Apo silicon oil objective of 1.3 NA (Olympus 562 
Corporation). 11 z planes were acquired per site (1µm step size) every 5 min for approximately 563 
12.5 hours. A 488nm laser was used to excite the GFP probe while emitted light was filtered 564 
by a 525/50 band pass filter and captured by a Prime BSI Scientific CMOS camera (2048 × 565 
2048 pixels, Teledyne Photometrics). Images were deconvolved using Huygens Professional 566 
19.10 software (Scientific Volume Imaging) using up to 40 iterations of the Classic Maximum 567 
Likelihood Estimation algorithm with a theoretical PSF. Background correction was automatic. 568 
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The signal-to-noise ratio setting was adjusted empirically to 16 to give satisfactory results. 569 
Image analysis was performed on the resulting image series using FIJI (version 2.0.0) and the 570 
Bio-Formats Importer plugin. Appropriate single z-planes were then selected for further image 571 
analysis and display. 572 
 573 
Immunostaining and immunofluorescence: 574 
Cells were grown in 0.2% gelatine-coated 35-mm glass bottom chambers (Ibidi; 80826), fixed 575 
in 4% formaldehyde in PBS for 10 min at room temperature, washed three times in PBS, 576 
permeabilized for 5 min at room temperature in PBS supplemented with 0.1% Triton X-100 577 
and 0.25% BSA (Sigma-Aldrich), and washed twice in PBS. Corresponding primary (anti-578 
H3K9me3: ab8898 (abcam), anti-H3K27me3: C15410195 (diagenode), anti-GFP: 579 
11814460001 (Millipore) and secondary antibodies (Alexa Fluor 488 anti-mouse and 568 anti-580 
rabbit IgGs from ThermoFisher) were diluted in PBS containing 2% FBS and 0.02% BSA. 581 
Primary antibody incubations were performed overnight at 4°C. Secondary antibody 582 
incubations were performed for 1h at room temperature. Following antibody incubations, cells 583 
were washed once with PBS and incubated for 10 min with PBS containing 4’,6-diamidino-2-584 
phenylindole dihydrochloride (DAPI, 0.5 μg/ml) for 10 minutes at room temperature to stain 585 
DNA. Following three washing steps in PBS, cells in multi-well plates were kept in PBS for 586 
imaging. Randomly selected cells were imaged with sequential acquisition settings on a Leica 587 
SP5 inverted confocal laser scanning microscope. 588 
 589 
Generation of recombinant nucleosomes: 590 
Xenopus H3 and H4 and human H2A and H2B were expressed from pET-3a or pET-3d 591 
vectors in BL21 (DE3) pLysS for H3, H2A, and H2B or BL21 (DE3) for H4 through induction 592 
with 0.2 mM IPTG for 4 h at 37°C. Histones were purified from inclusion bodies and solubilised 593 
in unfolding buffer (20 mM Tris-HCl pH 7.5, 7 M guanidine HCl, 10 mM DTT). Extracted 594 
histones were dialysed against three changes of urea dialysis buffer (10 mM Tris HCl pH 8, 595 
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7 M urea, 100 mM NaCl, 1 mM EDTA, 5 mM beta-mercaptoethanol, this and all subsequent 596 
histone dialysis steps were carried out at 4°C) and then purified further by passing over a 597 
HiTrap Q column (GE Healthcare) before binding to and NaCl gradient elution from HiTrap SP 598 
cation exchange chromatography columns (GE Healthcare). Fractions containing histones 599 
were pooled and dilaysed three times against water containing 5 mM beta-mercaptoethanol 600 
and lyophilised for long-term storage at -80°C. To express histones for native chemical ligation 601 
(NCL), constructs encoding truncated Xenopus histone H3 were generated in pET-3a. For 602 
generation of H3K4me3-modified histones, truncated H3 lacking residues 1-31 after the 603 
initiator methionine, with a threonine-to-cysteine substitution at position 32 of Xenopus H3 and 604 
a cysteine-to-alanine substitution at position 110 (H3D1–31 MT32C C110A) was expressed in 605 
BL21 (DE3) pLysS and purified as above, except for the final dialysis, which was carried out 606 
as two rounds of dialysis against 1 mM DTT in H2O and one round against 0.5 mM TCEP 607 
before lyophilisation and storage. For generation of H3K27me3-modified histones, a similarly 608 
truncated Xenopus H3 construct was used, lacking the first 44 residues and carrying a 609 
threonine-to-cysteine mutation at residue 45 (H3D1–45 MT45C C110A).  610 
Native chemical ligation reactions were carried out in 6 M Guanidine HCl, 250 mM sodium 611 
phosphate buffer pH 7.2, 150 mM 4-mercaptophenylacetic acid (MPAA), 50 mM TCEP for 612 
72 h at room temperature with constant agitation. Reactions were then dialysed three times 613 
against urea dialysis buffer (see above, but with 1 mM DTT instead of 5 mM beta-614 
mercaptoethanol). Ligated full-length modified histones were separated from unligated histone 615 
through cation exchange chromatography on a HiTrap SP column (GE) and then dialysed 616 
against three changes of water containing 5 mM beta-mercaptoethanol before lyophilization 617 
and storage at -80°C until use. For H3K4me3 and H3K4me1-modified histones, H3D1–31 618 
MT32C C110A was reacted with a synthetic peptide spanning residues 1–31 of histone H3.1 619 
containing tri- or mono-methylated lysine at position 4 and a C-terminal benzyl thioester 620 
(Peptide Protein Research Ltd., Fareham, UK). For H3K27me3-modified histones, H3D1–44 621 
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MT45C C110A was reacted with a synthetic peptide spanning H3.1 residues 1–44 including 622 
trimethylated lysine at position 27 and a C-terminal benzyl thioester.  623 
To reconstitute histone octamers, the four core histones were resuspended in unfolding buffer 624 
(see above), mixed in a mass ratio of 1:1:1.2:1.2 (H3:H4:H2A:H2B), and dialysed against three 625 
changes of refolding buffer (10 mM Tris HCl pH 8, 2 M NaCl, 1 mM EDTA, 5 mM beta-626 
mercaptoethanol) at 4°C. After centrifugation to remove precipitate formed during dialysis, 627 
correctly assembled histone octamers were purified by size exclusion chromatography in 628 
refolding buffer on a S200 column (GE Healthcare) using an Akta PURE system (GE 629 
Healthcare). DNA template for mononucleosome assembly was generated by PCR with a 630 
biotinylated forward primer, amplifying a 209-bp fragment centered around the 147-bp 601 631 
nucleosome positioning sequence, followed by PCR purification and elution into TE buffer. To 632 
reconstitute recombinant mononucleosomes, DNA and histone octamers were combined in 633 
refolding buffer supplemented with 5 M NaCl to compensate for reduction in NaCl 634 
concentration due to introduction of TE buffer with the DNA, followed by gradient dialysis 635 
against TE buffer down to 400 mM NaCl and then a step dialysis against TE buffer at 4°C. 636 
Optimal ratios of DNA and histone octamer were determined so that at least 95% of DNA was 637 
complexed, but without over-assembly and unspecific DNA binding of histones. Assemblies 638 
were routinely checked by native gel electrophoresis on 6% acrylamide gels in TGE buffer.  639 
 640 
Bacterial expression of eCR-eGFP-His fusion proteins: 641 
eCR-eGFP fusion proteins were expressed in BL21 (DE3) E. coli by induction for 3 h at 37°C 642 
with 0.5 mM IPTG in the presence of 20 µM ZnCl2. Cells were resuspended in lysis buffer 643 
(20 mM Tris HCl pH 8, 500 mM NaCl, 0.1% NP-40, 0.5 mM PMSF) and lysed by sonication. 644 
Lysates were cleared by centrifugation at 23,000 g for 30 min at 4°C. Cleared lysates were 645 
incubated with Sepharose 6 Fast Flow Ni-NTA resin (GE Healthcare) for 1 h. All purification 646 
steps were carried out at 4°C. Beads for collected by brief centrifugation at 800 g, 647 
resuspended in 10 ml of 300 mM wash buffer (50 mM NaH2PO4 pH 8, 300 mM NaCl, 20 mM 648 
imidazole, 0.1 mM PMSF), and transferred to a 10-ml polyprep column (Biorad). Settled beads 649 
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were then washed once with 10 ml of 1 M wash buffer (see above, but with 1 M instead of 650 
300 mM NAcl), and once with 5 ml of wash buffer (see above, but without PMSF), before 651 
elution with 5 ml elution buffer (50 mM NaH2PO4 pH 8, 300 mM NaCl, 250 mM imidazole), 652 
collecting 0.5-ml fractions. Fractions were analysed by Bradford protein assay (Biorad) and 653 
SDS-PAGE. Fractions containing the desired eCR-eGFP fusion protein were pooled and 654 
dialysed against three changes of BC100 (20 mM HEPES KOH pH 8, 100 mM KCl, 655 
10% glycerol, 0.5 mM DTT) at 4°C and re-analysed by Bradford and SDS-PAGE. 656 
 657 
Nucleosome pulldown assays: 658 
For pulldown assays with recombinant modified nucleosomes and eCR-eGFP fusion proteins, 659 
streptavidin sepharose high performance beads (GE Healthcare, 8 µl of slurry per pulldown) 660 
were briefly washed three times with pulldown buffer (20 mM HEPES KOH pH 7.9, 150 mM 661 
NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF, 0.1% NP-40). All centrifugation 662 
steps were carried out at 1,500 g for 2 min at 4°C. All incubation steps were carried out at 4°C. 663 
After washes, beads were incubated overnight with 3 µg of assembled recombinant 664 
nucleosomes (in TE diluted with pulldown buffer and adjusted to 0.1% NP-40 and 150 mM 665 
NaCl final concentration by addition of 10% NP-40 and 5 M NaCl, respectively) with constant 666 
rotation in the cold room. Beads were then collected by centrifugation and washed briefly with 667 
three changes of pulldown buffer. Bead-bound nucleosomes were then incubated with 668 
increasing amounts of eCR-eGFP fusion proteins for 2 h under constant agitation in the cold 669 
room. Beads were then washed with pulldown buffer by 5-min incubation under rotation. For 670 
TAF3 Phd eCR fusions, two washes with pulldown buffer containing NP-40 followed by three 671 
washes in pulldown buffer without NP-40 were performed. For CBX7 Chromo eCR fusions, 672 
four washes in pulldown buffer with NP-40 followed by two washes without NP-40 were carried 673 
out. After washes, bound proteins were eluted from beads by boiling for 5 min at 95°C with 674 
1.5x SDS sample buffer (95 mM Tris HCl pH 6.8, 15% glycerol, 3% SDS, 75 mM DTT, 675 
0.15% bromophenol blue). Protein binding was analysed by Western Blotting with anti-His 676 
antibody (Sigma, H10229), anti-H4 antibody (Cell Signaling Technology, 13919), anti-677 
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H3K4me3 (abcam, ab8580), and anti-H3K27me3 (Cell Signaling Technology, 9733). 40% of 678 
bound sample was loaded along with 20% of input samples. 679 
 680 
Biotin chromatin immunoprecipitation (bio-ChIP): 681 
For cross-linking and chromatin extraction, 30–50 × 10^6 cells were harvested by 682 
trypsinisation, washed once, and fixed for 8 min with 1% formaldehyde at room temperature 683 
in medium containing DMEM (Invitrogen), supplemented with 15% foetal bovine serum (FBS; 684 
Invitrogen) followed by the addition of glycine (final concentration 0.12 M) and incubation for 685 
10 min on ice. Cells were collected by centrifugation at 680 g for 5 min and washed twice with 686 
10 ml DPBS. After last wash, cells were resuspended in 10 ml buffer containing 0.25% Triton 687 
X-100, 1 mM EDTA, 10 mM TRIS, 0.5 mM EGTA, and 200 mM NaCl and incubated for 10 min 688 
on ice followed by centrifugation at 680 g for 5 min. Final cell lysis was performed in MNase 689 
Digest Buffer (20 mM Tris (pH 8.0), 5 mM MgCl2, 1 mM CaCl2, 10 mM NaCl, 0.25 M Sucrose, 690 
1 % Triton-X100 and 1x EDTA-free complete protease inhibitor cocktail (PIC, Roche; 691 
COEDTAF-RO)) in a concentration-dependent volume (2x 10^4 cells per μl) for 1h on ice. For 692 
Mnase digestion, cross-linked chromatin was incubated at 37 °C for 2 minutes followed by 693 
addition of 50U Mnase per ml and additional incubation at 37 °C for 20 minutes. Digestion was 694 
stopped by addition of stop-buffer (150mM NaCl, 100 mM EDTA, 200 mM EGTA) followed by 695 
addition of SDS to a final concentration of 0.1% and 4 cycles (32/50 seconds ON/OFF) 696 
sonication in a Bioruptor Pico instrument (Diagenode) according to the manufacturer's 697 
instructions. Fragmented chromatin was centrifuged at 12,000 g for 10 min at 4°C and 698 
supernatant was used for further steps. Streptavidin-M280 magnetic beads were blocked for 699 
1 h with 1% cold fish skin gelatine (Sigma Aldrich) and 100 ng tRNA (Sigma Aldrich) 700 
supplemented with protease inhibitor cocktail mix (Roche) and washed twice with buffer 3 with 701 
0.1% SDS and 150 mM NaCl. Chromatin (150–200 μg) was then incubated with 90 μl pre-702 
blocked streptavidin-M280 magnetic beads overnight at 4°C. Beads were washed under 703 
rotation for 8 min for each wash step and placed on a magnetic rack for 2 min for exchange 704 
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of buffers first with two rounds of 2% SDS, high salt buffer (50 mM HEPES pH 7.5 (adjusted 705 
with KOH), 500 mM NaCl, 1mM EDTA, 1 % Triton-X100, 0.1 % deoxycholate, 0.1% SDS), 706 
DOC buffer (250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA, 10 mM TRIS), and 707 
two rounds of Tris/EDTA buffer. Beads were treated with RNaseA (60 μg, Roche) for 30 min 708 
at 37°C in 1% SDS, 0.1 M NaHCO3, and subsequently proteinase K (60 μg, Roche) for 3 h at 709 
55°C in 1% SDS, 0.1 M NaHCO3, 10 mM EDTA, 20 mM TRIS, followed by de-cross-linking 710 
overnight at 65°C. DNA was purified with phenol–chloroform extraction and ethanol 711 
precipitation. 712 
 713 
Antibody chromatin immunoprecipitation (AbChIP): 714 
For cross-linking and chromatin extraction, 30–50 × 10^6 cells were harvested by 715 
trypsinisation, washed once, and fixed for 8 min with 1% formaldehyde at room temperature 716 
in medium containing DMEM (Invitrogen), supplemented with 15% foetal bovine serum (FBS; 717 
Invitrogen) followed by the addition of glycine (final concentration 0.12 M) and incubation for 718 
10 min on ice. Cells were collected by centrifugation at 680 g for 5 min and washed twice with 719 
10 ml DPBS. After last wash, cells were resuspended in 10 ml buffer containing 0.25% Triton 720 
X-100, 1 mM EDTA, 10 mM TRIS, 0.5 mM EGTA, and 200 mM NaCl and incubated for 10 min 721 
on ice followed by centrifugation at 680 g for 5 min. Final cell lysis was performed in Mnase 722 
Digest Buffer (20 mM Tris (pH 8.0), 5 mM MgCl2, 1 mM CaCl2, 10 mM NaCl, 0.25 M Sucrose, 723 
1 % Triton-X100 and 1x EDTA-free complete protease inhibitor cocktail (PIC, Roche; 724 
COEDTAF-RO) in a concentration-dependent volume (2x 10^4 cells per μl) for 1h on ice. For 725 
Mnase digestion, cross-linked chromatin was incubated at 37 °C for 2 minutes followed by 726 
addition of 50U Mnase per ml and additional incubation at 37 °C for 20 minutes. Digestion was 727 
stopped by addition of stop-buffer (150mM NaCl, 100 mM EDTA, 200 mM EGTA) followed by 728 
addition of SDS to a final concentration of 0.1% and 4 cycles (32/50 seconds ON/OFF) 729 
sonication in a Bioruptor Pico instrument (Diagenode) according to the manufacturer's 730 
instructions. Fragmented chromatin was centrifuged at 12,000 g for 10 min at 4°C and 731 
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supernatant was used for further steps. 50 ul per IP of protein-A/G magnetic beads (Invitrogen) 732 
were blocked for 1 h at 4 °C with 100 ng tRNA (Sigma Aldrich) and 100 ng BSA (Sigma Aldrich) 733 
supplemented with 1 x protease inhibitor cocktail mix (PIC, Roche), washed twice with 1 x TE 734 
and taken up in 50 ul/IP 1 x TE and 1 x PIC. 100 μg of Chromatin were then pre-cleared with 735 
20 μl pre-blocked protein A/G magnetic beads for an hour at 4 °C. After bead removal, 5 ug/IP 736 
of antibody were added (H3K27me3: Diagenode, C15410195, H3K4me3: abcam, ab8580, 737 
H3K9me3: abcam, ab8898) at 4 °C under over-night rotation. 30 ul of blocked beads were 738 
added for another 3-4 hours of immunoprecipitation. Beads were washed at 4 °C under 739 
rotation for 8 min for each wash step and placed on a magnetic rack for 2 min for exchange 740 
of buffers with two rounds of high salt buffer (50 mM HEPES pH 7.5 (adjusted with KOH), 500 741 
mM NaCl, 1mM EDTA, 1 % Triton-X100, 0.1 % deoxycholate, 0.1% SDS), one round of DOC 742 
buffer (250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA, 10 mM TRIS), and two 743 
rounds of Tris/EDTA buffer. Beads were treated with RNaseA (60 μg, Roche, RNASEA-RO) 744 
for 30 min at 37°C in 1% SDS, 0.1 M NaHCO3, and subsequently proteinase K (60 μg, Roche) 745 
for 3 h at 55°C in 1% SDS, 0.1 M NaHCO3, 10 mM EDTA, 20 mM TRIS, followed by de-746 
crosslinking overnight at 65°C. DNA was purified with Qiagen MinElute Kit according to 747 
manufacturer’s instructions and eluted in 10-20 ul elution buffer. 748 
 749 
ChIP-seq library preparation, high-throughput sequencing and read pre-processing: 750 
For ChIP-seq, libraries were prepared using the NEB-next ChIP-seq library Kit (E6240) 751 
following the standard protocols. Up to 8 samples with different index barcodes were 752 
combined at equal molar ratios and sequenced as pools. Sequencing of library pools was 753 
performed on Illumina HiSeq 4000 or Nova Seq machines according to Illumina standards, 754 
with 75- to 150-bp single-end sequencing. Library demultiplexing was performed following 755 
Illumina standards. Samples were filtered for low-quality reads and adaptor sequences 756 
removed using Trim Galore (https://github.com/FelixKrueger/TrimGalore). Filtered reads were 757 
mapped to the mouse genome (version mm9) using the BOWTIE algorithm allowing for two 758 
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mismatches and only unique mappers were used (-m 1 --best --strata). Identical reads from 759 
PCR duplicates were filtered out.  760 
 761 
Selection of genomic coordinates and data analysis:  762 
To obtain genome-wide 1kb intervals, we partitioned the entire genome into 1 kb sized tiles. 763 
Intervals overlapping with satellite repeats (Repeatmasker), ENCODE black-listed and low 764 
mappability scores 70 (below 0.5) were removed in order to reduce artefacts due to annotation 765 
errors and repetitiveness. To detect eCR-enriched regions, we utilised MACS2 using the 766 
eGFP ChIP-seq as background and applying the following parameters: --broad -g mm --broad-767 
cutoff 0.1. To detect antibody-specific peaks for histone modifications, we applied the same 768 
approach but using input chromatin as a background signal. Obtained histone modification 769 
peaks were further filtered according to qval >= 2 and pileup >= 3.4 scores.  770 
Peaks were overlapped with genomic features and coverages were calculated using the 771 
following hierarchy: promoters, enhancers, exons, repeats and introns. Promoters were 772 
defined as +/- 1kb around RefSeq gene TSS, enhancers were defined based on DHS peaks 773 
where H3K4me1 was higher than H3K4me3 71, exons and introns were retrieved based on 774 
RefSeq annotations, and repetitive elements using Repeatmasker. ChromHMM segmentation 775 
72 of the mouse genome was obtained from http://compbio.mit.edu/ChromHMM/ , as part of 776 
ENCODE. 777 
For Figure 1e, a genomic range object containing all peaks was generated, overlapping peak 778 
regions were merged, and finally used to compute correlations between eCR and antibody 779 
signals. To define H3K4me3-monovalent, H3K27me3-monovalent and bivalently-marked 780 
peaks, we calculated the H3K4me3 and H3K27me3 enrichments at these sites and selected 781 
all H3K4me3 peaks devoid of H3K27me3 as H3K4me3-monovalent peaks. H3K27me3 782 
lacking H3K4me3 signals were selected as H3K27me3-monovalwent while H3K4me3 peaks 783 
positive for H3K27me3 were selected as bivalent peaks. 784 
ChIP enrichments at genomic segments and peaks were calculated as log2-fold changes over 785 
input chromatin (for antibodies) and over eGFP (for eCRs) after library size normalization and 786 
 32 
using a constant of eight pseudo counts to reduce sampling noise. Heatmap and average 787 
density-profiles around peaks were generated using genomation in R (Akalin et al, 2014).  788 
 789 
Mass spectrometry analysis of histone modifications: 790 
Histones were processed as described in Feller et al. 2015 with modifications as described 791 
below. De-crosslinked histones were separated by SDS-PAGE on 16 % Novex Tris-Glycine 792 
gels (Invitrogen, XP00165BOX), stained with InstantBlue (Expedeon, ISB1L) and bands 793 
corresponding to core histones were excised. Gel pieces were washed twice with water and 794 
twice with 100 mM ammonium bicarbonate. Gel pieces were destained by incubating three 795 
times for each 10 minutes with 50 mM ammonium bicarbonate/50% acetonitrile at 37 °C with 796 
shaking at 800 rpm in a Thermomixer. Gel pieces were successively dehydrated by incubating 797 
with 100 mM ammonium bicarbonate, once 20 mM ammonium bicarbonate and three times 798 
with acetonitrile. Histones were twice derivatized by chemical acetylation by reacting 5 µL of 799 
d6-acetic anhydride ((CD3CO)2O, Sigma-Aldrich), 15 µL of 100 mM ammonium bicarbonate 800 
and 1 M ammonium bicarbonate buffered with 1:2 diluted ammonium hydroxide solution to 801 
keep the pH at 8. The reactions were performed for 45 minutes at 37 °C with shaking at 800 802 
rpm in a Thermomixer. After the derivatization reactions, histones were washed four times 803 
with 100 mM ammonium bicarbonate, two times with water, and three times with acetonitrile. 804 
Histone gel pieces were rehydrated with a 25 ng/ul trypsin solution in 100 mM ammonium 805 
bicarbonate (sequencing-grade trypsin from Promega) and digested overnight at 37 °C. 806 
Tryptic peptides were extracted twice with 70% acetonitrile/0.25% TFA and twice with 807 
acetonitrile, vacuum concentrated in a speed vacuum centrifuge and resuspended in 100 mM 808 
ammonium bicarbonate. Free peptide N-termini were derivatized twice by reacting 5 µL of d6-809 
acetic anhydride, 30 µL of 1 M ammonium bicarbonate and 10-15 µL of 1:2 diluted ammonium 810 
hydroxide solution to keep the pH at 8. After the reaction mixture was vortexed and incubated 811 
at 37 °C for 45 minutes with shaking at 800 rpm in a Thermomixer, it was quenched with 35 812 
µL of 1 M ammonium bicarbonate, the solution volume was reduced to 15 µL in a speed 813 
vacuum centrifuge and the derivatization procedure was repeated. After derivatization, 814 
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peptides were evaporated in a speed vacuum centrifuge at 37 °C to near dryness, 815 
resuspended in 20 µL of 0.1% trifluoroacetic acid (TFA), the pH was adjusted with 50% TFA 816 
solution to pH 2 and the peptides were purified by a StageTip protocol using two discs of C18 817 
followed by one disc of activated carbon (3 M Empore). After StageTip purification, the 818 
samples were evaporated in a speed vacuum centrifuge to near dryness and stored until mass 819 
spectrometry acquisition. Before MS analysis, the histone peptides were resuspended in 20 820 
µL of 0.1% TFA and diluted 1:10 in 0.1% TFA supplemented with iRT reference peptides 821 
(Biognosis).  822 
The MS-ready histone solution was separated on a reverse phase liquid chromatography 823 
column (Waters Acquity HSS T3, C18, 1.8 µM). The column was connected to a nanoflow 824 
UPLC (Waters M-Class) and peptides were electrosprayed in a Q Exactive HF mass 825 
spectrometer (Thermo Fisher Scientific). Buffer A was composed of 0.1% formic acid in HPLC-826 
grade water and buffer B was 0.1% formic acid in acetonitrile. Peptides were eluted in a linear 827 
gradient with a flow rate of 300 nL per minute, starting at 1% B and ramping to 35% in 55 min, 828 
followed by an increase to 45% B in 5 min, followed by an increase to 65% in 3 min followed 829 
by an increase to 98% in 5 min and then holding at 98% B for another 10 min. The mass 830 
spectrometer was operated in data-independent acquisition mode, ion chromatograms were 831 
extracted with Skyline and data summarization and statistical analysis was performed in R 832 
and Excel (Feller and Aebersold, manuscript in preparation). In brief, a spectral-chromatogram 833 
library was constructed using isotopically-labelled reference synthetic peptides and manually 834 
curated spectra from cellular histone preparations. To identify and quantify histone 835 
modifications, Thermo raw files were imported into the Skyline histone template and peak 836 
identification and ion chromatogram extraction was performed using the spectral-837 
chromatogram library. All peak integrations were manually validated. Relative abundances of 838 
acetylated peptidoforms were calculated using the extracted ion chromatograms for all 839 
peptides that share the same sequence, including the unmodified peptide, according to the 840 
formulas described previously 29.  841 
 842 
 34 
Nuclear extraction for ChromID:  843 
Cells were cultured with ES medium and induced for the corresponding time periods (12-24 844 
hours) with 50μM biotin (Sigma) dissolved in DPBS. Cells were grown to about 90% 845 
confluency on 15cm dishes (approximately 50 x 10^6 cells), harvested by trypsinisation, and 846 
pelleted by centrifugation at 1000 rpm for 5min. The subsequent steps were either performed 847 
on ice or at 4°C. Pellets were gently resuspended (by shaking) in 5 pellet volumes (PV) of 848 
nuclear extract buffer 1 (NEB1; 10mM HEPES pH7.5, 10mM KCl, 1mM EDTA, 1.5mM MgCl2, 849 
1mM dithiothreitol (DTT), and 1x PIC) and swelled on ice for 10 minutes, followed by 850 
centrifugation at 2000 g for 10 minutes. Pellets were then gently resuspended in 2x PV of 851 
NEB1, followed by dounce homogenisation using a loose pistil (10 times up and down). Nuclei 852 
were collected by centrifugation at 2000 g for 10 minutes and resuspended in 1x PV of NEB1 853 
+ 12μl/ml of Benzonase (Millipore, 71206) to digest genomic DNA, followed by overhead 854 
rotation at 4°C for three hours. Nuclei were then pelleted by centrifugation at 2000 g for 10 855 
minutes, resuspended in 1x PV of NEB2-450 (20mM HEPES pH 7.5, 0.2mM EDTA, 1.5mM 856 
MgCl2, 20% glycerol, 450mM NaCl, 1mM DTT, and 1x PIC), Dounce homogenised using a 857 
tight pistil (10 times up and down), vortexed, followed by overhead rotation at 4°C for one 858 
hour. Cell debris were removed by centrifugation at 2000 g for 10 minutes. The salt 859 
concentration of the nuclear extracts (NE) was adjusted to 150mM by drop-wise addition of 2x 860 
residual volume of NEB2-NS (see above, without NaCl), and NP40 levels were adjusted to 861 
0.3%. Subsequently, protein concentrations were measured using QubitTM Protein Assay Kit 862 
(Thermo Fisher Scientific, Q33211). Equal amounts of proteins were used per IP (standard: 2 863 
mg) and protein lysate volumes were adjusted to equal volumes with IP buffer (IPB; NEB2-864 
150, 0.3% NP40, 1mM DTT, and 1x PIC).  865 
 866 
Streptavidin beads preparation for affinity purification:  867 
Streptavidin M-280 Dynabeads (Thermo Fisher) were equilibrated three times with IPB (see 868 
above) by overhead rotation for 10 minutes at 4°C and subsequently pre-blocked in IPB + 1% 869 
cold fish gelatin rotating 4°C for one hour. Finally, beads were taken up in IPB (same volume 870 
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as starting volume). 40 μl of pre-blocked Streptavidin M-280 beads were added to lysates and 871 
incubated overnight rotating at 4°C.  872 
 873 
High stringency washes and on-bead digestion for ChromID: 874 
After incubation of nuclear lysates with beads rotating at 4°C overnight, beads were separated 875 
from the unbound fraction on a magnetic rack and washed twice with 2% SDS in TE (+ 1mM 876 
DTT, 1x PIC) for 10 minutes rotating overhead at room temperature (RT), once with high salt 877 
buffer (HSB; 50mM HEPES pH 7.5, 1mM EDTA, 1% Triton X-100, 0.1% deoxycholate, 0.1% 878 
SDS, 500mM NaCl, 1mM DTT, and 1x PIC) for 10 minutes at RT, once with DOC buffer 879 
(250mM LiCl, 10mM Tris pH 8.0, 0.5% NP40, 0.5% deoxycholate, 1mM EDTA, 1mM DTT, 880 
and 1x PIC) for 10 minutes at 4°C, and twice with TE buffer (+ 1mM DTT, 1x PIC) for 10 881 
minutes at 4°C. After the washes, beads were isolated from the last TE wash on a magnetic 882 
rack and the proteins were digested with 0.5 μg trypsin (Promega; V5111) in 40ul digestion 883 
buffer (1M Urea in 50mM Tris pH 8.0, 1mM Tris-(2-carboxyethyl)-phosphin (TCEP)) directly 884 
on beads, overnight at 26°C and shaking at 600 rpm. Next day, the digested protein-peptide 885 
mix was isolated from beads and reduced with 2mM TCEP for 45 minutes at RT, and then 886 
alkylated with 10mM Chloroacetamide (ClAA) for 30min at RT in the dark. The digestion was 887 
stopped the next day by acidifying the peptides with Trifluoracetic acid (TFA) to a final 888 
concentration of 0.5%, and the Acetonitrile (ACN) concentration was adjusted to 3% prior 889 
loading on C18 StageTips.  890 
 891 
C18 StageTips clean-up:  892 
Obtained petides were cleaned-up using in-house produced (Functional Genomics Center 893 
Zurich, FGCZ) C18-StageTips. First, these were humidified with 100% methanol (MeOH), 894 
cleaned twice with 60% ACN; 0.1% TFA, and conditioned twice with 3% ACN; 0.1% TFA. 895 
Then, peptides were loaded onto the StageTips, and the collected flow-through was loaded 896 
again. Afterwards, the peptides were desalted twice with 3% ACN; 0.1% TFA, and finally 897 
eluted twice with 60% ACN; 0.1% TFA. Desalted peptides were shock frozen in liquid nitrogen 898 
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(N2), completely dried in a speed vacuum centrifuge, and subsequently resolved in 3% ACN; 899 
0.1% formic acid (FA), containing internal retention time (iRTs, Biognosys) standard peptides.  900 
 901 
Detection of biotinylated proteins by data-dependent acquisition (DDA) mass spectrometry: 902 
We used an Easy-nLC 1000 HPLC system operating in trap / elute mode (trap column: 903 
Acclaim PepMap 100 C18, 3um, 100A, 0.075x20mm; separation column: EASY-Spray C18, 904 
C18, 2um, 100A, 0.075x500mm, Temp: 50°C) coupled to an Orbitrap Fusion mass 905 
spectrometer (Thermo Scientific). Trap and separation column were equilibrated with 12 ul 906 
and 6 ul solvent A (0.1 % FA in water), respectively. 2 µl of the resuspended sample solution 907 
was injected onto the trap column at constant pressure (500 bar) and peptides were eluted 908 
with a flow rate of 0.3 µl/min using the following gradient: 2 % - 25 % B (0.1 % FA in ACN) in 909 
50 min, 25 % - 32 % B in 10 min an 32 % - 97 % B in 10 min. After 10 min of washing by 97 910 
% B. High accuracy mass spectra were acquired with an Orbitrap Fusion mass spectrometer 911 
(Thermo Scientific) using the following parameter: scan range of 300-1500 m/z, AGC-target 912 
of 4e5, resolution of 120’000 (at m/z 200), and a maximum injection time of 50 ms . Data-913 
dependent MS/MS spectra were recorded in top speed mode in the linear ion trap using 914 
quadrupole isolation (1.6 m/z window), AGC target of 1e4, 300 ms maximum injection time, 915 
HCD-fragmentation with 30 % collision energy, a maximum cycle time of 3 sec, and all 916 
available parallelizable time was enabled. Mono isotopic precursor signals were selected for 917 
MS/MS with charge states between 2 and 7 and a minimum signal intensity of 5e3. Dynamic 918 
exclusion was set to 25 sec and an exclusion window of 10 ppm. After data collection, the 919 
peak lists were generated using automated rule-based converter control 73 and Proteome 920 
Discoverer 2.1 (Thermo Scientific).  921 
 922 
Protein identification and label-free protein quantification of DDA data:  923 
Protein identification and label-free quantification was done with MaxQuant (version 1.5.3.30) 924 
using the Andromeda search engine and label-free quantification (LFQ) 74. The mouse 925 
reference proteome (UniProtKB/Swiss-Prot and UniProtKB/TrEMBL) version 2018_12 926 
 37 
combined with manually annotated contaminant proteins was searched with protein and 927 
peptide FDR values set to 0.01. All MaxQuant parameters can be found in the uploaded 928 
parameterfile: rpx40_mqpar.xml (deposited in the PRIDE repository). Perseus (versions 929 
1.6.1.1) was used for statistical analysis 75. Results were filtered to remove reverse hits and 930 
proteins only identified by site. Further, only proteins found in at least 3 replicates were kept. 931 
Missing values were imputed from a 1.8 standard deviations left-shifted Gaussian distribution 932 
with a width of 0.3 (relative to the standard deviation of measured values). Potential interactors 933 
were determined using a t-test and visualised by a volcano plot. Significance lines were 934 
determined by a permutation-based method 76 with an FDR value of 0.01 and S0 values (curve 935 
bend) of 0.1 to 1 (details shown in volcano plots). Obtained results were exported and further 936 
visualised using the statistical computer language R (version 3.5.2).  937 
 938 
Estimation of protein abundance by data-independent acquisition (DIA)  939 
Cells were grown to about 90% confluency on 10 cm dishes (approximately 15 x 10^6 cells), 940 
harvested by trypsinisation, and pelleted by centrifugation at 1000 rpm for 5 min. Cell nuclei 941 
were extracted following the nuclear extraction procedure (described above) until digestion of 942 
genomic DNA. Nuclei were then pelleted by centrifugation at 2000 g for 10 minutes and 943 
resuspended in 30 µl lysis buffer (4% (w/v) SDS, 100 mM Tris/HCL pH 8.2). Lysate was 944 
incubated at 95 °C for 5 min under 1000 rpm shaking, followed by centrifugation at 16000 g 945 
for 10 minutes at RT. Supernatant was processed immediately using FASP (Wisniewski et al, 946 
2009) using 50 µg of total protein as measured by Qubit Protein Assay Kit (Q33211, 947 
ThermoFisher). Tryptic peptides were cleaned-up using in-house produced C18-StageTips. 948 
Peptides were resuspended in 3% acetonitrile, 0.1% formic acid in water including iRT 949 
peptides (Biognosys, Schlieren, Switzerland).  950 
All Data-independent acquisition (DIA) was performed on an Orbitrap Fusion Lumos mass 951 
spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled online to a Acquity UPLC M-952 
class (Waters, Milford, MA) using a PicoView 565 nanospray source (New Objective). Peptide 953 
mixtures were separated in a single-pump trap/elute mode, using a trapping (nanoEase 954 
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Symmetry C18, 5 μm, 180 μm × 20 mm) and an analytical column (nanoEase HSS T3 C18, 955 
100 Å, 1.8 μm, 75 μm x 250 mm). Solvent A was water, 0.1% formic acid and solvent B was 956 
acetonitrile, 0.1% formic acid. 0.5 µg peptides/sample were loaded with a constant flow of 957 
0.5% solvent B, at 15 μL/min onto the trapping column. Trapping time was 0.5 min. Peptides 958 
were eluted via the analytical column with a constant flow of 300 nL/min. During the elution 959 
step, the percentage of solvent B increased in a nonlinear fashion from 8% to 22% in 82 min 960 
and 22% to 32% in 8 min.  961 
In brief, following MS settings were applied: MS1 scan at 120’000 Orbitrap resolution with an 962 
AGC target of 1 × 10^6 and max. injection time of 118 ms in the mass range of 350 to 1205 963 
m/z, followed by 50 DIA scans covering a precursor mass range of 400 to 1000 m/z with 964 
isolation window widths of 12 m/z. The scan resolution in the Orbitrap was set to 15’000 with 965 
an AGC target of 1 × 10^6 and max. injection time of 25 ms. The HCD collision energy was 966 
set to 30%.  967 
Data Analysis. In brief, raw files were analysed in Spectronaut Pulsar (13.9.191106.43655, 968 
Biognosys) by library-free DirectDIA. The basic principles of DirectDIA analysis have been 969 
previously described by Tsou et al. (DOI: 10.1038/nmeth.3255). The searches were done 970 
against the mouse reference proteome (UniProtKB/Swiss-Prot) and the GFP reference. 971 
Search results were filtered at 1% FDR on precursor and protein group level. Only the top 3 972 
peptides were used for label-free protein intensity calculation. The protein group report of 973 
significant proteins was further used for plotting in R. 974 
 975 
Functional gene set enrichment and network visualisation: 976 
All proteins identified previously were mapped to human STRING identifiers via the gene 977 
names and sequence similarity. Functional gene set enrichment was performed using the 978 
“Proteins with Values/Ranks” functionality in STRINGv11 61 for each chromatin reader. The 979 
log2 fold changes over background were used. From all terms enriched in any of the chromatin 980 
readers, nine Gene Ontology Cellular Component terms (The Gene Ontology Consortium, 981 
2019) which were significantly enriched in at least one of the readers were selected. 982 
 39 
Cytoscape (version 3.7.1) was used to layout the 79 proteins that were identified in ChromID 983 
experiments and are members of at least one of the selected GO terms. Visualisation was 984 
based on GO term membership only. Each protein was represented by a pie chart which 985 
signifies in which reader the protein was significantly detected after LS-MS/MS. STRING 986 
interaction confidences were added as links between proteins, with a cutoff set at confidence 987 
0.4. For foreground protein network visualisation, all proteins with a positive log2 fold change 988 
in any of the chromatin readers compared to nBASU were considered as foreground. Their 989 
protein-protein interaction network was retrieved from STRINGv11 61 with an interaction 990 
confidence threshold of 0.7. The network was imported into Cytoscape (version 3.7.1) and 991 
visualized using the “Prefuse Force Directed OpenCL Layout”. 992 
 993 
Data access:  994 
All sequencing datasets produced in this study have been deposited to the NCBI Gene 995 
Expression Omnibus under the accession: GSE128907. Additional sequencing datasets 996 
from other publications are listed in the Supplementary Table 3. The mass spectrometry 997 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 998 
partner repository with the dataset identifier PXD014483.   999 
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Figure Legends 1000 
 1001 
Figure 1 - Nuclear and genomic localisation indicates correct eCR interactions with the 1002 
genome 1003 
a) Top: chromatin reader domains used in this study and their specificities towards chromatin 1004 
marks. Bottom: schematics of constructs utilised to generate mouse embryonic stem cells 1005 
expressing engineered chromatin readers (eCRs). eCRs are composed of single or dual 1006 
chromatin reader domains fused in frame to eGFP and a biotin acceptor site (see also 1007 
Supplementary Fig. 1a). b) Recombinase-Mediated Cassette Exchange (RMCE) followed by 1008 
double selection (Ganciclovir and Puromycin) was applied to generate stable integration of 1009 
the expression construct at a defined site in the mouse genome. Stably expressed eCRs are 1010 
in vivo biotinylated by a bacterial BirA ligase. c) Live imaging shows nuclear localisation of 1011 
single and dual eCRs in mouse ES cells. Nuclear eGFP serves as control (See also 1012 
Supplementary Fig. 2). Size bars = 5 µm. d-f) Genome browser examples showing correct 1013 
localisation of eCRs according to chromatin modifications detected by antibody-ChIP-seq and 1014 
DNA methylation by MeDIP-seq. For histone-PTM readers, only eCRs with two reader 1015 
domains are shown (See supplementary Fig. 3 for single-domain eCRs). Shown is the library-1016 
normalised read density at 100bp intervals. Gene models and the position of CpG islands and 1017 
repetitive elements are indicated. g) Pearson correlation score obtained from comparisons of 1018 
eCRs with chromatin modifications at selected genomic intervals positive for the interrogated 1019 
chromatin modifications.   1020 
 1021 
Figure 2 - Functional analysis indicates dependency on reader domains and modifications for 1022 
correct eCR localisation.  1023 
 1024 
a-b) Genome browser examples for loss of binding of mutant-eCRs to sites enriched by wild 1025 
type eCRs. Shown is the library-normalised read density at 100bp intervals. Gene models and 1026 
the position of CpG islands and repetitive elements are indicated. c) Genome browser 1027 
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example for loss of CBX7-2xChromo-eCR binding to the genome in absence of H3K27me3 in 1028 
Eed-KO cells. d) Box plots showing loss of binding of mutant eCRs to sites bound by their 1029 
wild-type versions. In addition, removal of binding substrates such as DNA methylation (Dnmt-1030 
TKO) or H3K27me3 (Eed-KO) results in loss of binding of wild-type eCRs to the corresponding 1031 
sites. Shown are log2-FC enrichments at peak regions identified for the wild-type eCRs in wild 1032 
type cells. Boxes denote the IQR and whiskers 1.5 IQR. e) Heatmap showing the histone-1033 
PTM log2-FC enrichment scores obtained from CBX1-2xChromo and TAF3-2xPhd eCR ChIP. 1034 
Histone-PTMs are clustered based on enrichment scores. Colour code below the heatmap 1035 
indicates histone isoforms and modification types detected in this assay. f-g) Bar plots 1036 
showing enrichment/depletion for selected histone-PTMs, and the effect of combinatorial 1037 
serine-10 phosphorylation on CBX1-2xChromo binding. Error bars indicate the standard 1038 
deviation from two independent replicate measurements. 1039 
 1040 
Figure 3 - ChromID identifies proteins associated with H3K9me3 and DNA methylation.  1041 
a) Schematic describing ChromID using engineered chromatin readers fused to promiscuous 1042 
biotin ligases (BioL). b) Volcano plot showing ChromID results obtained using the CBX1-eCR-1043 
BASU targeting H3K9me3 over a reader-free nuclear BASU (nBASU) control. Statistically-1044 
enriched proteins are indicated (FDR-corrected t-test, FDR = 0.01, n = 4 independent 1045 
replicates). Peptides used to identify CBX1 match the Chromodomain used in the eCR. c) Bar 1046 
plots representing the top 10 cellular component GO terms enriched by CBX1-eCR-BASU. 1047 
The combined score is calculated by multiplying the ln(p-value) from Fisher's exact test and 1048 
the z-score.  d) Heatmap representation of significantly enriched proteins captured with the 1049 
5mC-reader (MBD1-eCR-BASU) and compared to results obtained using a mutant 5mC-1050 
reader (R22A-eCR-BASU). Shown are average LFQ intensities (log2-FC) from four 1051 
independent measurements. Peptides used to identify MBD1 match the MBD domain used in 1052 
the eCR. e) Same as in c, but for proteins enriched by MBD1-eCR-BASU. 1053 
 1054 
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Figure 4 - Generation and validation of eCRs reading bivalent H3K4me3 and H3K27me3 1055 
marks. 1056 
a) Genome browser example showing context-dependent localisation of dual-reader eCRs to 1057 
bivalent sites decorated by H3K4me3 and/or H3K27me3. Binding is preferentially directed to 1058 
bivalent sites, while regions modified by H3K4me3- or H3K27me3-only show less recruitment. 1059 
Gene models and the position of CpG islands and repetitive elements are indicated. b) Scatter 1060 
plots indicating the distribution (highlighted data points) and enrichment (colour) for the tested 1061 
eCRs along the mouse genome based on H3K27me3 and/or H3K4me3 marks. Shown is the 1062 
enrichment of H3K27me3 and H3K4me3 at 1kb windows covering the entire genome (grey). 1063 
Coloured data points indicate the top 1% genomic windows enriched by the indicated eCR. 1064 
eCRs specific for one modification separate towards their respective substrates, while the dual 1065 
reader localises predominantly to the bivalent-modified sites (See also Supplementary Fig. 1066 
11d). c) Average density profiles around H3K4me3- (red) and H3K27me3-monovalent (blue) 1067 
or bivalent-peaks (green). Data indicates increased preference of the dual-reader eCR for the 1068 
bivalent peaks while binding at H3K4me3- and H3K27me3-only peaks is strongly reduced 1069 
(See also Supplementary Fig. 11e).  1070 
 1071 
Figure 5 - ChromID identifies the proteome associated with key chromatin marks in mouse 1072 
ES cells. 1073 
a) Bar plots representing the top 10 cellular component GO terms enriched at H3K4me3-, 1074 
H3K27me3- and bivalently-modified chromatin. b) Genome browser example for 1075 
FLASH/CASP8AP2 co-localising at transcribed histone genes marked with H3K4me3. c) 1076 
Heatmap representation of proteins significantly-enriched in either of the ChromID 1077 
experiments specific for H3K9me3-, H3K4me3-, H3K27me3- or bivalently-modified chromatin 1078 
in mouse ES cells (FDR-corrected t-test, FDR = 0.01, n = 4 independent replicates). The LFQ 1079 
intensities (log2-FC) over nBASU are shown. d) Network analysis based on proteins belonging 1080 
to major cellular component GOs terms identified in all ChromID experiments. Individual 1081 
proteins are shown as nodes, edges indicate interactions retrieved from the STRING database 1082 
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(interaction score > 0.9). Proteins detected in ChromID experiments but not called significant 1083 
by the t-test are shown as grey nodes. Significantly enriched proteins are coloured according 1084 
to the reader they have been identified. e) Heatmap representation of identified factors 1085 
classified based on their functionality and clustered according to the computed LFQ intensities 1086 
(log2-FC/nBASU). Proteins were selected based on min 0.5 log2-FC in at least one ChromID 1087 
experiment.   1088 
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Supplementary Figures 1089 
 1090 
Supplementary Figure 1  1091 
a) Constructs used to integrate and express eCRs in mouse stem cells. eCR variants are 1092 
available using either one or two readers domains in tandem. Triangles: LoxP sites; CAG: 1093 
CAGGS promoter; bio: biotin acceptor site; NLS: nuclear localisation signal; eGFP: enhanced 1094 
green fluorescence protein; IRES: internal ribosomal entry site; PAC: Puromycin N-Acetyl-1095 
transferase; 2A: 2A self-cleavable peptide. The 2A self-cleavable peptide enables to generate 1096 
eCRs lacking GFP, which we used to test the influence of GFP on genome-wide eCR binding 1097 
in Supplementary Fig. 2c. b) FACS profiles showing stable and homogenous expression of 1098 
various eCRs in mouse ES cell lines. c) Barplots displaying protein abundances in eCR cell 1099 
lines measured by direct-DIA. Top 3 precursors per peptide were used for quantity calculation 1100 
of reference proteins (grey) and eCR-GFP fusion protein (green). Proteins were ordered from 1101 
high to low protein abundance. d) Western blot analysis comparing protein levels of 1102 
endogenous CBX1 and CBX1-eCR using an antibody specific for the CBX1 Chromodomain 1103 
in nuclear extracts obtained from ES cells expressing either the eGFP-only or the CBX1-1104 
2xChromo-eCR constructs. LaminB1 is used as a loading control.  e-f) FACS measurements 1105 
of ES cell-derived neuronal progenitor cells after embryoid body dissociation shows identical 1106 
percentage and distribution of cells expressing the neuronal surface marker CD24. ES cells 1107 
were used as negative controls. e) indicates the percentage of positive cells and f) the CD24 1108 
intensity in the cell population. g) Microscopy images of in vitro derived neurons shows 1109 
successful differentiation of neuronal cells derived from control ES cells and ES cells 1110 
expressing eCRs. 1111 
 1112 
 1113 
Supplementary Figure 2  1114 
a) Live-cell imaging showing nuclear localization of single and dual eCRs. Nuclear eGFP 1115 
serves as control and shows exclusion from mitotic chromosomes. Size bar = 5 µm. b) Fixed-1116 
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cell imaging comparing H3K9me3 localisation and CBX1-2xChromo eCR localisation by 1117 
antibody staining. c) Comparison between fixed-cell and live-cell imaging using the CBX1-1118 
2xChromo eCR highlights the suitability of eCRs to study localisation on M-phase 1119 
chromosomes. d) Live-cell imaging examples of stably-expressed dual eCRs in mouse ES 1120 
cells showing localization to interphase chromosomes. Nuclear eGFP serves as control and 1121 
shows exclusion from mitotic chromosomes. Size bar = 5 µm. e) Typical filmstrips of time-1122 
lapse fluorescence imaging of proliferating cells in the GFP control cell line (Top, from movie 1123 
S1) and the H3K27me3 reader (CBX7-eGFP-eCR) expressing cell line (Bottom, from movie 1124 
S2). Cells undergoing division are circled in yellow and were imaged at 5-min intervals. Size 1125 
bar = 5 µm. f) Western blot detection of His-tagged eCRs enriched using reconstituted 1126 
nucleosomes modified by either H3K4me3 or H3K27me3. Experiments were performed with 1127 
three different amounts of the indicated eCRs expressed from E.coli. Left panel shows 1128 
pulldowns performed using H3K4me3-modified mononucleosomes against TAF3-1xPhd or 1129 
TAF3-2xPhd eCRs, and right panel using H3K27me3 against CBX7-1xChromo or 2xChromo. 1130 
 1131 
Supplementary Figure 3  1132 
a-b) Genome browser examples for 1 x domain-eCR and 2 x domain-eCR localisation 1133 
according to chromatin modifications and full-length proteins containing the reader domains 1134 
(where available). Histone modifications were detected based on antibody-ChIP-seq. Shown 1135 
is the library-normalised read density at 100bp intervals. Gene models and the position of CpG 1136 
islands and repetitive elements are indicated. c) Cross-correlation matrix showing the 1137 
genome-wide association of eCRs with histone modifications. Pearson's correlation score was 1138 
calculated based on read counts at 1 kb intervals covering the entire genome. Regions with 1139 
low mappability scores were removed from this analysis. d) Scatterplots showing binding of 1140 
the eCRs to all analysed chromatin marks. Data points represent log2-transformed read 1141 
counts at 1 kb intervals along the mouse genome. Pearson's correlation coefficient is 1142 
indicated.  1143 
 1144 
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Supplementary Figure 4  1145 
a) Top: Scatterplots comparing binding of eCRs to binding data obtained from the full-length 1146 
proteins containing the respective reader domains. Bottom: Scatterplots comparing binding of 1147 
the full-length proteins to the respective chromatin modifications. Data points represent log2-1148 
transformed read counts at 1 kb intervals along the mouse genome. Pearson's correlation 1149 
coefficient is indicated. b) Heat maps of histone modifications and eCR binding to peaks 1150 
identified based on antibody ChIP-seq data for H3K4me3, H3K27me3 and H3K9me3. These 1151 
results indicate a good agreement in binding of eCRs to the corresponding marks. Note that 1152 
H3K4me3 and H3K27me3 have a substantial overlap due to bivalently modified regions. c) 1153 
Box plots showing similar enrichments of eCRs and histone modifications at peaks identified 1154 
using H3K4me3, H3K27me3 and H3K9me3 data sets (same as in b). Enrichment is calculated 1155 
as log2-fold change of ChIP-seq reads over corresponding input reads. Boxes denote the 1156 
inter-quartile range (IQR) and whiskers 1.5 ICR. d) Bar plots showing the percentage of 1157 
histone modification peaks (red:H3K4me3, green:H3K9me3, blue:H3K27me3) covered by 1158 
peaks identified in the eCR ChIP-seq data. Increased coverage of H3K4me3 peaks by the 1159 
H3K27me3 readers (CBX7-eCR, dPC-eCR) is due to the strong overlap between H3K27me3 1160 
and H3K4me3 peaks at bivalent sites in mouse ES cells. Coverage was calculated based on 1161 
base pairs overlapping the indicated peak sets.  1162 
 1163 
Supplementary Figure 5 1164 
a-b) Box plots showing enrichment of chromatin marks at peaks identified using individual 1165 
eCR data sets. Histone modification enrichment is calculated as log2-fold change of ChIP-seq 1166 
reads over input reads. DNA methylation is calculated as percentage of methylated cytosines 1167 
in the peak region using whole genome bisulphite sequencing (WGBS) data. Boxes denote 1168 
the inter-quartile range (IQR) and whiskers 1.5 ICR. c) ChromHMM-based seven-state 1169 
segmentation of the mouse ES cell genome based on four histone marks. Segmentation was 1170 
obtained from ENCODE/UCSC and table indicates the model parameters used. d) Box plots 1171 
showing enrichment of chromatin marks and eCRs at the seven states obtained from 1172 
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ChromHMM. Enrichments are calculated as log2-fold change of ChIP-seq reads over input 1173 
reads. Boxes denote the inter-quartile range (IQR) and whiskers 1.5 ICR. e) Stacked bar plots 1174 
showing the eCR and histone modification peak-coverage distribution among various genomic 1175 
features. Coverage was calculated based on base pairs overlapping between the peaks and 1176 
the indicated features. “Genome-wide” the coverage proportions of the used features in the 1177 
mouse genome. f) Scatterplots showing increased binding specificity of eCRs containing two 1178 
reader domains to their binding substrates. Data points represent log2-fold changes calculated 1179 
based on read counts at 1 kb intervals of 2 x domain eCRs over 1 x domain eCRs (y-axis) 1180 
versus log2-fold enrichment of ChIP over input for histone marks (x-axis). Pearson’s 1181 
correlation is indicated. 1182 
 1183 
Supplementary Figure 6 1184 
a) FACS profiles comparing expression levels and expression homogeneity in the cell 1185 
population for cell lines expressing wild type and mutant eCR. b) Immunofluorescence 1186 
indicates localisation of wild type and mutant eCRs in wild type ES cells and wild type eCRs 1187 
in mutant cell lines (Eed-KO and Dnmt-TKO). Size bar = 5 µm. c) Genome browser example 1188 
for loss of binding of mutant-MBD-eCRs to sites enriched by wild type eCRs. Shown is the 1189 
library-normalised read density at 100bp intervals. d) HPLC-MS measurement of 1190 
methylcytosine and cytosine indicates absence of methylation in the Dnmt-TKO clones used 1191 
here. Error bars denote standard deviation from three independent replicate measurements. 1192 
e) Western blot analysis validates loss of H3K27me3 in the Eed-KO cell lines. Histone H1 and 1193 
H3 serve as loading controls. f) Scatterplots showing loss of binding to chromatin substrates 1194 
for wild CBX7-Chromo- or MBD-based eCRs in cell lines lacking H3K27me3 or DNA 1195 
methylation, respectively. Shown are log2-fold changes between eCRs mapped in wild type 1196 
and mutant ES cells (y-axis) versus the respective modification in wild type cells (x-axis) either 1197 
as log2-fold enrichment of histone modifications over input chromatin, or local concentration 1198 
of methyl-CpGs (log2 / 100bp based on WGBS data) for MBD-eCRs. Data points are 1199 
calculated based on 1kb intervals.  1200 
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 1201 
Supplementary Figure 7 1202 
a) Schematics indicating the histone-PTM quantification procedure, involving eCR-dependent 1203 
chromatin enrichment by ChIP, followed by PAGE purification of histones, and MS-based 1204 
detection of histone-PTMs (See Methods). b) Brilliant Blue-stained PAGE gels indicate 1205 
separation of histones obtained from eCR pulldowns (elute) and corresponding input 1206 
chromatin after de-crosslinking. Red rectangle indicates the size-range range used to excise 1207 
histone bands from the gel. c) Western blot detection of His-tagged TAF3-2xPhd eCRs 1208 
enriched using reconstituted nucleosomes unmodified or modified by either H3K4me1 or 1209 
H3K4me3. Anti-Histone H4 serves as a pull-down control. d) Scatter plots indicating the 1210 
distribution (highlighted data points) and enrichment (colour) for the indicated eCRs along the 1211 
mouse genome based on H3K9me3 and/or H4K20me3 marks. Shown is the enrichment of 1212 
H3K9me3 and H4K20me3 at 1kb windows covering the entire genome (grey). Coloured data 1213 
points indicate the top 1% genomic windows enriched by the indicated eCR. The CBX1-eCR 1214 
localises predominantly to sites that contain H3K9me3, irrespective of presence of 1215 
H4K20me3. b) Boxplots indicating CBX1-2xChromo and H3K9me3 (AbChIP) enrichments at 1216 
genomic intervals containing H3K9me3 & H4K20me3 and at sites that contain H4K20me3 in 1217 
absence of H3K9me3.   1218 
 1219 
Supplementary Figure 8  1220 
a) Constructs used to integrate and express eCRs fused to promiscuous biotin ligases in 1221 
mouse stem cells. Control constructs consist of nuclear reader-free promiscuous biotin 1222 
ligases. Triangles: LoxP sites; CAG: CAGGS promoter; bio: biotin acceptor site; NLS: nuclear 1223 
localisation signal; 13xGGGGS: flexible long linker 33; BioL: promiscuous biotin ligase; 2A: 2A 1224 
self-cleavable peptide; eGFP: enhanced green fluorescence protein; IRES: internal ribosomal 1225 
entry site; PAC: Puromycin N-Acetyl-transferase. b) Streptavidin Western blot to test the 1226 
labelling efficiency of three different promiscuous biotin ligases without a chromatin reader 1227 
domain (BirA* R118G-mutant, BioID2 and BASU) in mouse stem cells for the indicated time 1228 
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points. c) Heatmap representation of significantly-enriched proteins captured with the 1229 
H3K9me3-reader fused to BASU (CBX1-eCR-BASU) or BioID2 (CBX1-eCR-BioID2). Shown 1230 
are LFQ intensities (log2-FC). d) Volcano plots showing ChromID results obtained using 1231 
CBX1-eCR-BioID2 (left) or CBX1-eCR-BASU (right) targeting H3K9me3 over a reader-free 1232 
nuclear BioID2 (nBioID2) or reader-free nuclear BASU (nBASU) control (24h induction). 1233 
Statistically enriched proteins are indicated (FDR-corrected t-test, n = 4 individual replicates). 1234 
e) Heatmap representation of enriched proteins (top) or background proteins (bottom) 1235 
captured with the H3K9me3-reader fused to BASU (CBX1-eCR-BASU) after three different 1236 
biotin induction times (1, 6 and 24 hours). Shown are LFQ intensities (log2-FC).  1237 
 1238 
Supplementary Figure 9  1239 
a) Endogenous tagging strategy for Znf280D, allowing for the insertion of a Flag-bio peptide 1240 
at the C-terminal end of the protein using Cas9 and donor ssDNA. b) Sanger sequencing to 1241 
confirm correct in-frame insertion of the Flag-bio peptide sequence. c) Genome browser 1242 
examples showing localisation of ZNF280D at sites positive for H3K9me3 and bound by the 1243 
CBX1-2xChromo eCR.  d) Average density profiles and heat maps over all ZNF280D peaks 1244 
indicating increased H3K9me3 localisation at ZNF280D-bound sites.  1245 
 1246 
Supplementary Figure 10  1247 
a) Volcano plots showing ChromID results obtained using MBD1-eCR-BASU (left) or the 1248 
binding mutant 5mC-reader (R22A-eCR-BASU) over nBASU control (12h induction). 1249 
Statistically enriched proteins are indicated (FDR-corrected t-test, n = 4 individual replicates). 1250 
b) Principal component analysis for all ChromID samples shown in f) indicates clustering 1251 
based on identified proteins. c) Heatmap representation of enriched proteins captured with 1252 
MBD1-eCR-BASU, nBASU and the binding mutant 5mC-reader (R22A-eCR-BASU) after 12h 1253 
biotin induction. Shown are LFQ intensities (log2-FC). 1254 
 1255 
Supplementary Figure 11 1256 
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a) Schematic indicating the setup of the dual-reader eCR, specific for H3K27me3 and 1257 
H3K4me3. b) FACS profiles comparing expression levels and expression homogeneity in cell 1258 
lines expressing wild type and mutant dual-reader eCRs. c) Genome browser example 1259 
showing context-dependent localisation of dual-reader eCRs to bivalent sites decorated by 1260 
H3K4me3 and H3K27me3. d) Scatter plots indicating the distribution (highlighted data points) 1261 
and enrichment (colour) for the tested eCRs along the mouse genome based on H3K27me3 1262 
and/or H3K4me3 marks. Same representation as in Fig. 4b. e) Box plots showing enrichment 1263 
of the bivalent eCRs at genomic regions containing only H3K27me3 or H3K4me3 and regions 1264 
bivalently modified by H3K4me3 and H3K27me3. Regions were identified based on antibody-1265 
ChIP-seq peaks, specific for H3K4me3 or H3K27me3. Enrichments are calculated as log2-1266 
fold change of ChIP-seq reads over input reads. Boxes denote the inter-quartile range (IQR) 1267 
and whiskers 1.5 ICR. f) Cross-correlation matrix based on 1kb genomic intervals covering 1268 
the entire mouse genome, showing correlations between H3K27me3, H3K4me3 and 1269 
monovalent eCRs.  1270 
 1271 
Supplementary Figure 12 1272 
a) Genome browser example showing loss of localisation to bivalent sites for dual-reader 1273 
eCRs containing mutated Cromo- or Phd-domains. b) Heat map summarising the correlation 1274 
of all tested eCRs with CpG density, H3K4me3 and H3K27me3 at 1 kb windows covering the 1275 
entire genome. c) Average density profiles around genomic regions enriched for H3K4me3-1276 
only (red), H3K27me3-only (blue) or bivalently modified by both marks (green), showing loss 1277 
of binding for bivalent eCRs containing mutations in either the H3K27me3- or H3K4me3-1278 
reader domains. d) Genome browser example showing loss of localisation to bivalent sites for 1279 
dual-reader eCRs in ES cell lines lacking H3K27me3. e) Average density profiles showing 1280 
loss of binding for bivalent eCRs in absence of H3K27me3. Same as in c). 1281 
 1282 
Supplementary Figure 13  1283 
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a) List of significantly-enriched proteins detected in all ChromID experiments (FDR-corrected 1284 
t-test, FDR = 0.01, n = 4 individual replicates). Asterisks indicate proteins with chromatin 1285 
reader domains specific for the respective mark. b) Heatmap representation of the significantly 1286 
enriched proteins captured with each eCR-BASU targeting H3K4me3-, H3K27me3- and 1287 
bivalently-modified chromatin in mouse ES cells (FDR-corrected t-test, FDR = 0.01, n = 4 1288 
individual replicates). The LFQ intensities (log2-FC) over nBASU are shown. c) Box plots 1289 
showing enrichment of the H3K9me3 and H3K27me3-specific eCRs at genomic regions 1290 
enriched by either CBX1-2xChromo (green) or CBX7-2xChromo (blue). This indicates lack of 1291 
cross-reactivity between H3K27me3 and H3K9me3 readers. Enrichments are calculated as 1292 
log2-fold change of ChIP-seq reads over input reads. Boxes denote the inter-quartile range 1293 
(IQR) and whiskers 1.5 ICR. d-e) Volcano plots showing ChromID results obtained using 1294 
either d) the CBX7-2xChromo or e) bivalent CBX7-Chromo+TAF3-Phd in ES cells lacking 1295 
H3K27me3 (Eed-KO). Statistically enriched proteins are indicated (FDR-corrected t-test, n = 1296 
4 individual replicates).   1297 
 1298 
Supplementary Figure 14  1299 
a) Genome browser example showing identical localisation between the same eCRs fused to 1300 
either eGFP or BASU. Shown are biotin-ChIP-seq datasets using the TAF3-2xPhd and the 1301 
CBX7-Chromo+TAF3-Phd constructs. b) Cross-correlation matrix based on 1kb genomic 1302 
intervals covering the entire mouse genome, showing correlations between eGFP or BASU 1303 
eCRs, together with H3K27me3, H3K4me3 and H3K9me3. c) Scatterplots somparing binding 1304 
of the eCRs fused to eGFP and BASU. Data points represent log2-transformed read counts 1305 
at 1 kb intervals along the mouse genome. Pearson's correlation coefficient is indicated. 1306 
 1307 
Supplementary Figure 15 1308 
a) Principal component analysis based on detected protein intensities separates the nBASU 1309 
controls and eCRs into distinct groups, with the H3K4me3 proteome and the H3K9me3 1310 
proteome showing the largest variation. The H3K9me3 and H3K27me3 datasets group closer 1311 
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to each other, and the bivalent dataset forms a separate group between the H3K4me3 and 1312 
H3K27me3, suggesting overlapping proteomes. b) Venn diagram showing the overlap of all 1313 
significantly enriched proteins using eCRs specific for DNA methylation and H3K9me3. 1314 
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